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Summary.
The single commonest cause of cancer deaths among women is breast cancer, 
closely followed by lung cancer. As detection methods and treatments improve, the 
rate of breast cancer deaths will hopefully fell. Surgical removal of all clinically 
apparent disease is usually the treatment of primary breast cancer, often followed by 
adjuvant systemic treatments to treat subclinical metastases. There are several 
appropriate adjuvant systemic treatments, however, the one favoured for hormonally 
sensitive cancer is endocrine therapy. This treatment is based on the concept that 
certain tumour cells will retain their sensitivity to hormones (e.g. oestrogen and 
progesterone). The aim of this type of therapy must therefore be to negate or reverse 
the proliferative effects of such influential hormones.
While it is accepted by clinicians that antiestrogens and progestins provide effective 
treatment of advanced hormone-sensitive breast cancer, long term usage leads to drug 
resistance and relapse. A possible approach to overcoming the mechanism of 
resistance could be to use short bursts of alternative endocrine therapies. Leake et al., 
(1992) demonstrated that a treatment with Tamoxifen and Megace could give 
significant advantages when compared to Tamoxifen alone. However, at the end of the 
progestin component of the cycle there was onset of vaginal bleeding in 13% of 
patients. One possible solution could be the maintenance of a low level of
Norethisterone (lO'^M) through out the cycle. Studies contained within this thesis 
demonstrated that the Tamoxifen component of the cycle induced PR synthesis in ZR- 
75-1 cells. The ability of Tamoxifen to maintain PR synthesis was not impaired by the
presence of Norethisterone (1X10'^M). However, higher doses of this progestin did 
significantly reduce PR levels. Investigations into the effect of Tamoxifen and
progestin either alone or together on the proliferation on ZR-75-1 or MCF-7 cells 
revealed that Tamoxifen induced cell growth. Norethisterone plus Tamoxifen had no 
effect on either cell line. However, on its own, Norethisterone induced some growth 
inhibition on MCF-7 cells.
1 BREAST CANCER
1.1 BREAST CANCER:- The Current Situation
Breast cancer is the commonest single cause of cancer deaths among women in the 
United Kingdom (closely followed by lung cancer). There are 26,000 women who are 
newly diagnosed as having breast cancer each year and, of those, 16,000 will 
eventually die of their disease. It has been estimated that 1 in 12 women will develop 
breast cancer at some time in their lives. World-wide over half a million women 
develop breast cancer each year but half of these cases occur in western developed 
countries which contain less than one fifth of the female world population.
The annual incident rate of breast cancer shows an eight fold variation world-wide. 
The annual death rate is highest in England and Wales with 28.4 deaths per 100,000 
females. The United States has a lower rate of 22.1. The lowest incidence recorded is 
in Japan and is 5.8. Such international variation could suggest that there are genetic 
factors involved. However, the incidence of breast cancer in second generation 
Japanese living in the USA is the same as their Caucasian counterparts (Cancer 
Research Campaign, 1991). This suggests a role for social and/or environmental 
factors, including diet.
1.2 BREAST CANCER:- A Historical overview
Breast cancer has been a problem for treatment and prevention throughout the 
centuries. An Egyptian papyrus written in approximately 1600 BC is the earliest 
known reference to the disease (Moulin, 1983). It advocates no treatment other than 
cautery for ulcerated tumours. Surgery for breast tumours was later practised by 
Greek and Roman physicians. Records describe a prototype of radical mastectomy 
that was probably being performed in Rome around 100 BC. Greek and Roman 
medicine gave way to the barbarian societies of the so called Dark Ages when surgical 
treatments were no longer endorsed. Various doctrines adopted quasi-religious 
therapies that varied from mass prayer and the laying on of the hands, to topical
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applications concocted from assorted natural elements often of an unspeakable nature. 
The mastectomy was reduced to a punitive rather than a therapeutic role. However, 
the Renaissance saw the reintroduction of the mastectomy as a therapeutic surgical 
practice refined from Greco-Roman protocols. Arrival of anaesthesia and antiseptics 
had still to occur before advances were seen in patient survival and morbidity.
It was not until 1775 that Perceval Pott (Pott, 1963) first suggested that the 
development of the human female breast was under the influence of the female sex 
secretions. While repairing a bilateral groin hernia, he removed the normal ovaries of a 
twenty-three year old woman; the woman subsequently ceased to menstruate and 
experienced significant loss in breast size, but remained otherwise healthy. Two years 
later, a French surgeon, Henry Francoise LeDran (Baum, 1981) significantly advanced 
the hope of a surgical cure. He proposed the theory that the cancer began as a local 
disease, spreading first to the lymphatics and then on to the general circulation.
Further important observations were made as early as 1836 by Cooper who 
observed a correlation between tumour growth and the menstrual cycle (Cooper, 
1836). Sixty years later, at the end of the nineteenth century, Beatson reported that a 
relationship existed between the malignant growth of the breast and the ovary 
(Beatson, 1896). He described the regression of metastatic lesions of the breast of a 
thirty-three year old pre-menopausal woman after undergoing an oophorectomy. Boyd 
reiterated these views four years later (Boyd, 1900) The modem era of endocrine 
therapy for mammary cancer had begun.
Thirty years later oestrone and oestradiol-170 were characterised and proposed as 
oestrogen agents. However, it was not until after the second world war that 
oestrogens were proven to have a stimulatory affect on human breast cancer, 
reversing the benefits of ovarectomy (Pearson et al., 1954). However, at the same 
time it was discovered that pharmacological doses of oestrogen could suppress the 
growth of some tumours. The next decade saw the utilisation of new biochemical 
techniques to identify and estimate steroids in blood and urine samples.
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In 1952 Huggins and Bergensal reported that a bilateral adrenalectomy can induce 
remission of advanced breast cancer in post-menopausal women (Huggins et al., 
1952). Similar remissions were observed by Luft and by Pearson and Ray after 
hypophysectomy (Luft et al., 1958; Pearson et al., 1960). A molecular mechanism 
explaining the success of the above ablative endocrine therapies was slowly being 
pieced together. In 1959, oestrogens were shown to accumulate in the pituitary 
glands, mammary glands, uterus and vagina (Glascock and Hoekstra, 1959), which 
was consistent with the fact that glands responded to oestrogens (Folly, 1956). These 
observations were reiterated in 1960 by Jensen and Jacobson who found that tritiated 
oestradiol was specifically taken up by tissues that had a mitogenic response to the 
hormone. This suggested the existence of a protein that specifically bound oestrogen 
in target tissues and thus mediated its action. Therefore it was proposed that those 
tumours that responded to endocrine therapy would have oestrogen binding protein 
while those that failed did not (Jensen and Jacobson, 1960). Although not entirely 
accurate this hypothesis did provide impetus for a medical rather than a surgical 
endocrine treatment. The intracellular receptor for oestrogen predicted by Jensen et 
al., was discovered in 1968 by two groups, Jensen and Gorski (Jensen et al., 1968; 
Gorski et al., 1968). They proposed the now classical two step model where the 
steroid enters the cell, binds to a cytostolic protein that translocates to the nucleus and 
binds to an oestrogen responsive gene. Thus the importance of receptor in breast 
cancer had been established. Largely due to McGuire and co-workers it was found 
that oestrogen receptors were present in about two thirds of human breast cancers 
(between 60-70% of cases). Furthermore their concentration was relative to the age 
and the menstrual status of a patient and to the degree of differentiation of the tumour 
(McGuire et al., 1975). The progesterone receptor was commonly detected in those 
tumours that had oestrogen receptors in about 50% of oestrogen receptor positive 
patients (Horwitz et al., 1985). The progesterone receptor was also detected in about 
55% of all oestrogen negative patients.
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As early as 1953 attention was brought to the inhibitory effects of anti-hormones. 
Kottmeir provided evidence for the inhibitory role of progestins on ovarian 
carcinomas. Exthamoxytriphetol (MER-25) synthesised at the Merrel Pharmaceuticals 
company was found to block the utrotrophic effect of oestradiol on mice (Kottmeier, 
1953, Lemer and Jordan, 1990). Thus the precedent for the evaluation of a new form 
of endocrine therapy was established. During trials MER-25 was associated with 
unacceptable toxicities as an anti-tumour agent. However, the antiestrogen 
Tamoxifen developed in 1967 (Harper and Walpole, 1967) was found to have 
considerably fewer side-effects (Legha and Carter, 1976). In 1971 Tamoxifen first 
entered clinical trials in England (Cole et a l, 1971) and in 1978 the drug was 
approved by the FDA in the United States. From its initial introduction Tamoxifen 
(Nolvadex) proved to be an indispensable part of the clinicians arsenal in the treatment 
of preselected pre- and post-menopausal patients with any stage of breast cancer.
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1.3 CAUSATION OF THE DISEASE
1.3.1 Epidemiology
Over the past two decades there have been many epidemiological studies of the 
aetiological basis of human breast cancer. However, useful conclusions are hard to 
postulate due to the interplay of various factors. A study by Anderson (1974) 
demonstrated that at least two types of breast cancer exist; a familial associated 
cancer, passed from one generation to another which could possibly be divided into 
further subclasses of genetic lesions, and a sporadic type of cancer not associated with 
family history. Investigations into possible risk factors associated with sporadic human 
breast cancer demonstrated that the younger the woman's age at menarche 
(MacMahon et al., 1973) and the longer the duration elapsing between this event and 
the menopause, the higher the risk of breast cancer (Trichopoulos et al., 1972). 
Analysis of this and other data led to the oestrogen window hypothesis (Sherman and 
Korenman, 1974) which proposed that the role played by anovulatory cycles was the 
cause of breast cancer. This has subsequently been shown to be incorrect.
Contraception has provided women with the means to control their own fertility. 
Hence the variation in time between menarche and first pregnancy amongst cultures 
has increased; woman from westernised or industrial societies tend to have fewer 
children and wait longer for them. MacMahon et al., (1973) have managed to 
correlate early age at first pregnancy with a lower risk of breast cancer. This pattern 
could possibly be due to the short-term growth enhancement by elevated pregnancy 
oestrogens and progesterone on already generated clones, followed by a subsequent 
long-term protective effect induced by pregnancy terminal differentiation of 
susceptible mammary gland cells (Trichopoulos and Lippman, 1992). This hypothesis, 
therefore, predicts that pregnancy increases the short term risk of breast cancer in the 
mother before imparting a more substantial long-term reduction; this has been 
suggested by several reports (Pathak et al., 1986; Bruzzi et al., 1988; Williams et al.,
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1990). The early excess risk should be more pronounced in mothers of multiple births 
since multiple birth pregnancies are characterised by higher levels of oestrogen and 
progesterone than for single birth pregnancies (Hseich et al., 1993; Doherty, 1990). 
Subsequent births have little further influence on the chances of developing breast 
cancer (Tulinius et al., 1978). Women with breast cancer that had fewer children 
overall, on average, had their first child at a later age. It is known that a first birth 
beyond a cross-over age limit between 30 and 35 years increases rather than reduces 
the overall risk of breast cancer (Trichopoulos et al., 1983). Further factors may 
contribute to these observations, including diet, environment, cultural and genetic 
factors.
A further example can be observed when examining the low incidence of breast 
cancer in Asian women. It is widely believed that the relatively low fat diet of Asian 
women compared with the high fat of western women is responsible. However, 
studies attempting to link diet directly to breast cancer have largely been negative 
(Graham et al., 1982; Willett et al., 1987). No single dietary nutrient has been proven 
to contribute to the risk of breast cancer. Nevertheless, excessive calorific intake, 
combined with a sedatory lifestyle leading to excessive weight is thought to be a 
contributing factor (Albanes, 1987). Furthermore, a low protein diet experienced by 
the inhabitants of third world countries may delay the menarche; additionally the 
women may become pregnant on their first ovulation and may also become pregnant 
on several further ovulations. Women in the United States and Northern Europe tend 
to have diets in rich animal fats and proteins with the result that their first menstrual 
period is in their early teens (or before). Due to the dictation of their lifestyles, they 
may delay the first pregnancy, if at all, until twenty or more years. In conclusion, it is 
still not clear whether age of first menstruation, contrasting diet or environmental 
factors contribute the greater amount to the risk of breast cancer.
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1.3.2 Oral Contraception and Hormone Replacement Therapy
Oral contraceptives have been widely used since the early 1960's by women to 
control ovulation and most oral contraceptives (OC) contain an oestrogen in 
combination with a progestin (Piper and Kennedy, 1987). There is concern whether 
exogenous hormones; either as contraception or hormone replacement (HRT) may 
increase the risk of breast cancer because most of the known risk factors are related to 
steroid hormones. The results of studies of oral contraceptives and breast cancer 
indicate that OC use generally has no effect on the aggregate life-time risk of 
developing breast cancer (Wingo et al., 1993; WHO study 1990). However, under 
some circumstances there may be a slight increase in risk for young women taking the 
OC for a long time before their first pregnancy (Wingo et al, 1993; WHO study 
1990). This trend may be compensated by a possible decreased risk of breast cancer in 
older women (>45) using OC. The studies so far undertaken have involved women 
under the age of 60 years. In the fixture it will be possible to include older women who 
used OC permitting a more accurate assessment of the relationship between OC use 
and life-time risk.
Studies on the use of HRT have shown that a long term use may slightly increase the 
risk of breast cancer (Dupont and Page, 1991; Steinberg et a l , 1991). However, the 
beneficial effects of HRT in the prevention of osteoporosis, postponement of the onset 
of ischemic heart disease, improvement of the lipid profile and improved quality of life 
make it necessary for patients to be educated regarding HRT so that women can make 
their own decision regarding its therapeutic value.
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1.3.3 Genetic and Familial Factors
A family history of breast cancer is now a well-established risk factor for the disease 
(Kelsey, 1979). Population based studies have shown that inherited factors maybe 
responsible for 4% to 10% of all breast cancer cases (Risch et al, 1993; Hall et al, 
1990). The gene for early-onset familial breast cancer has been localised to the 
proximal portion of the long arm of the human chromosome 17 (Hall et al, 1990; 
Narod et al, 1991). A woman's risk of developing familial breast cancer is dependent 
upon how many relatives have had the disease and at the age that they developed their 
disease (Skolnick et al, 1990). The increased risk becomes sufficiently significant for 
counciling when the woman has more than two relatives with the disease prior to 
forty-five years of age.
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2 STEROIDS AND STEROID
RECEPTORS
10
2.1 STEROID BIOSYNTHESIS
Steroids are widespread in both plant and animal kingdoms, and to date well over 
225 naturally occurring steroids have been isolated and characterised. In addition, 
many other steroids and steroid analogues have been synthetically produced by 
pharmaceutical companies.
A steroid is an organic molecule whose structure is based on a tetracyclic ring 
system composed of four rings fused together with a specific stereochemistry (figure 
1). The four rings are designated A, B, C, and D, beginning at the lower left, and the 
carbon atoms are numbered beginning in the A ring. The three six member rings (rings 
A, B, and C) can adopt strain-free chair conformations. However, the steroids are 
constrained to a rigid conformation and cannot undergo ring flips. The basic ring 
structure can be subject to a wide array of modifications by introduction of hydroxyl 
or carbonyl substituents and by introduction of double or triple bonds. In addition, 
halogens, sulphydryl or amino groups may replace steroid hydroxyl moieties and 
heteroatoms such as nitrogen or sulphur can replace the ring carbons
In mammalian systems cholesterol is the precursor of the five major classes of 
steroid hormones:- mineralocorticoids, glucocorticoids, oestrogens, progestins, and 
androgens. The steroid hormones are synthesised by sets of cells organised into glands 
which are members of the endocrine system. For example, cortisol and aldosterone, 
are produced by cells in the adrenal cortex; oestradiol and progesterone are made by 
interstital cells in the ovaries; and testosterone is made by leydig cells in the testes.
Steroidogenic tissues may synthesise cholesterol de novo from acetate, this occurs 
mainly in the testis (Hechter et al., 1953). Other human steroidogenic cells derive 
most of their cholesterol from plasma low density lipoprotein (LDL) (Brown et al 
.,1979). The rate-limiting enzyme in cholesterol synthesis in adrenal cells is 3-hydroxy- 
3-methylgluteryl coenzyme A (HMGCoA) reductase which is suppressed by adequate
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The Steroid Skeleton
18 R
CH
CH
2
3
4 6
(R= different side chains)
Fig. 1 A representative diagram of the basic steroid skeleton.
concentrations of LDL (Mason and Rainey, 1987). The human body takes its major 
source of cholesterol from its diet. Both HMGCoA reductase and LDL receptor and 
LDL cholesterol uptake are stimulated by trophic hormones that stimulate 
steroidogenisis (Golos et al, 1985; Golos and Strauss, 1988). LDL cholesterol esters 
are taken up by receptor mediated endocytosis (Brown et al, 1979). The esters may 
then be stored directly in the cell or converted to free cholesterol for steroid hormone 
synthesis. Free cholesterol is insoluble in the aqueous cytosol and maybe transported 
to the mitochondria by a Sterol Carrier Protein 2 (SCP-2) (Chanderbhan et al, 1982; 
Chanderbhan et al, 1983; Tanaka et al, 1984). The flux of cholesterol across the 
mitochondrial membranes to the site of the first enzyme in the steroidogenic pathway, 
P450 side-chain cleavage (see) enzyme, is stimulated by a 30 amino acid activator 
peptide, derived from the carboxy terminus of glucose regulatory protein (Pedersen 
and Brownie, 1983; Pedersen and Brownie, 1987; Ting and Lee, 1988). This peptide 
has a short half-life and appears to be very sensitive to cyclohexhnide (Privalle et al, 
1983).
Most steroidogenic enzymes are members of the cytochrome P450 group of 
oxidases (Miller and Levine, 1987; Nebert and Gonzalez, 1987). The generic term 
cytochrome P450 encompasses a large number of oxidative enzymes, all of which 
consist of about 500 amino acids and contain a single heme group. They all exhibit a 
characteristic shift in the Sorbet absorbance peak from 420 to 450nmupon reduction 
with carbon monoxide, hence the term P450 (pigment 450). Most P450 enzymes can 
metabolise multiple substrates catalysing a broad array of oxidations. This is also 
applicable to each steroidogenic P450 enzyme.
There are four distinctive P450 enzymes involved in adrenal steroidgenesis. As 
previously mentioned P450scc is found in the mitochondria and is the cholesterol side 
chain cleavage enzyme. P450cl 1, is also found in mitochondria and mediates 11- 
hydroxylase, 18-hydroxylase and 18-methyl oxidase activity. P450cl7, found in the 
endoplasmic reticulum mediates both 17a-hydroxylase and 17, 20-lyase activities. 
P450c21, found in the endoplasmic reticulum mediates the 21-hydroxylation of both
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glucocorticoids and mineralcorticoids. P450aro is found in the endoplasmic reticulum 
of cells in the gonads and in many other cell types mediating the aromatization of 
androgens and oestrogens.
The P450scc protein is a multimer of 16 subunits totalling over 850,00 daltons and 
is hound to the inner mitochondrial membrane (Shikita and Hall 1973(a); Shikita and 
Hall, 1973 (b)). It mediates the conversion of cholesterol to pregnenolone (Halkersten 
et al, 1961), the first, rate limiting (Stone and Hechter, 1955), and hormonally 
regulated step in the synthesis of all steroid hormones (DiBlasio et al, 1987; Golos et 
al, 1987; Picado-Leonard et al, 1988). This involves three distinctive chemical 
reactions, 20a-hydroxylation, 22-hydroxylation and scission of the cholesterol side 
chain at the bond between carbon atoms 20 and 22 to yield pregnenolone and 
isocaproic acid.
Pregnenolone may (see Figure 2) undergo one of two conversions either 17a- 
hydroxylation to 17-hydroxypregenolone mediated by P450c 17 enzyme or converted 
to progesterone. The enzyme(s) catalysing this reaction is/are non-P450 enzyme(s) 
bound to the endoplasmic reticulum and mediate 3 (3-hydroxysteroid dehydrogenase 
and isomerase (isom) activities. After the synthesis of progesterone, this steroid is 
hydroxylated at the 21 position to yield deoxycorticosterone. Further hydroxylation 
mediated by P450cl 1 yields cortisol. P450cl 1 also mediates the three final steps in the 
synthesis of aldosterone from deoxycorticosterone (Yanagibashi et al, 1986).
17-hydroxypregnenolone may undergo scission of the C-17,20 carbon bond to 
yield dehydroepiandrosterone (DHEA) or 17-hydroxlation to 17a- 
hydroxyprogesterone. Progesterone can also undergo 17a-hydroxylation to form 17a- 
hydroxprogesterone and further scission to yield androstenedione. After the synthesis 
of 17a-hydroxyprogesterone this steroid is hydroxylated at position 21 to yield 11- 
deoxycortisol, and further 1 ip-hydroxylation yields cortisol. Androstenedione can be 
synthesised from DHEA. Andostenedione is converted to testosterone, mediated by 
17-ketosteroid reductase, principally in the testes (Kurosumi et al, 1986). Androgens
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P450scc
3I3HSD Isom P450c21 P450c11 P450c11
Pregnenolone —  ^  ^ Progesterone —  ^ DOC —► Corticosterone —► 180H Corticosterone
P450c17
P450c11
P450c17 Aldosterone
3PHSD Isom P450c21 P450c11
170H Pregnenolone —► —► 170H Progesterone —►!! Deoxycortisol —► Cortisol
P450c17
3PHSD Isom 4-
P450c17
17 Keto reductase P450 arom
DHEA Androstenedione ■> Testosterone •> Estradiol
Fig. 2 Principal pathways of human steroid hormone synthesis. Other quantitatively 
and physiological minor steroids are also produced. Initially the mitochondrial 
cytochrome P450scc mediates the conversion of cholesterol to pregnenolone. 
Pregnenolone may undergo two conversions to either 17-Hydroxypregenolone or 
progesterone. Further hydroxylation of progesterone yields deoxycorticosterone. 17- 
OH Pregnenolone may undergo scission to yield either dehdroepiandrosterone 
(DHEA) or 17-hydroxylation to 17a hydroxyprogesterone. Progesterone may 
undergo further conversion by P450cl7 to yield 17a-hydroxyprogesterone and 
androstenedione. 17a-hydroxyprogesterone may then be hydroxylated to yield 11- 
deoxycortisol and further hydroxylation yields cortisol. Androstenedione can also be 
synthesised from DHEA Andostenedione is converted by a non-P450 enzyme, 17 
Keto-reductase (also referred to as 17(3 steroid dehydrogenase) to testosterone which 
may then be converted to oestradiol by aromatase.
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can also undergo aromatisation to form oestrogen steroids principally in the ovaries, 
but also in pheripheral adipose tissue and in breast tumour tissue.
2.1.1 Steroid Receptor Superfamilv
Steroid hormone receptors mediate steroid action (Jensen et al., 1968), and like many 
transcription factors they are single polypeptides that organised into discrete 
functional domains. Receptors have been characterised for each of the steroid 
hormone families: oestrogen (ER; Green et al., 1986), progesterone (PR; Conneely et 
al., 1986), glucocorticoid (GR; Hollenberg et al., 1985), androgen (AR; Lubahn et 
al., 1988), mineralocorticoid (MR; Arriza et al., 1987), vitamin D3 (VD3R; 
McDonnell et al., 1987) and also, more recently, the receptor superfamily has been 
shown to include receptors for nonsteroid, seemingly unrelated molecules, such as 
thyroid hormone (TRs; Weinberger et al., 1986) and retinoic acid (RAR; Giguere et 
al., 1987). All receptors in the superfamily:
(1) bind hydrophobic ligands that travel through cell membranes 
freely.
(2) are found intracellularly (usually in the nucleoplasm) and are not 
associated with cell membranes.
(3) are activated by binding ligand.
(4) achieve high affinity for specific response elements in the DNA, once 
activated.
(5) probably pass through several stages of phosphorylation.
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(6) are associated with heat shock proteins when free of ligand.
(7) bind as dimers to hormone reponse elements which are palindromic 
in nature, causing gene activation.
These phenomena will be discussed in the following pages of this thesis.
2.1.2 Receptor Synthesis
Steroid receptors are believed to be synthesised on cytoplasmic microsomes from 
single mRNAs. Immunocytochemical evidence of perinuclear localisation of 
cytoplasmic receptors suggests that the synthesis of receptors in vivo may occur on 
the outer nuclear membrane, with the resultant protein either transversing the nuclear 
membranes, co-translationally or very shortly after synthesis (Tuohimaa et a l , 1988).
The progesterone receptor is unique among steroid receptors in that it exists as 
two isoforms, termed A and B. The molecular weights of the human PR isoforms, as 
deduced from complementary DNA (cDNA) sequence are 98k and 86k respectively. 
The two proteins are generated by initiation of translation at two in-frame ATGs. Two 
different oestrogen regulated promoters are responsible for the synthesis of isoform A 
and B specific human PR mRNA's (Kastner et al., 1990). The two human PR isoforms 
have been demonstrated to activate transcription differently at target gene promoters 
(Tora et al., 1988).
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2.1.3 Subcellular Localisation of Steroid Receptors
The subcellular localisation of the receptors was initially thought to be cytoplasmic 
in the absence of hormone and nuclear in its presence (Gorski et al., 1968; Jensen et 
al., 1968). This hypothesis was based upon cell homogenisation and fractionation 
studies. However, the availability of specific monoclonal antibodies and 
immunocytochemical analysis, has shown that the oestrogen (King and Greene, 1984; 
Press et al., 1989), progesterone (Press et al., 1989; Gasc et al., 1984; Perrot-Applant 
et a l, 1985), and androgen (Husmann et al., 1990; Sar et al., 1990) receptors to be 
intranuclear even in the absence of their ligands. By contrast the glucocorticoid (Fuxe 
et al., 1985; Wikstrom et al., 1987) and mineralocorticoid receptors (Farman et al., 
1991; Lombes et al., 1990) seem to be either cytoplamic or both cytoplasmic and 
nuclear in the absence of hormone, and accumulate in the nucleus in its presence (Fuxe 
et a l, 1985). In vitro mutagenesis studies of cloned receptors has led to the 
description of nuclear localisation signals in glucocorticoid (Picard and Yamamoto,
1987), and oestrogen receptors (Guiochon-Mantel et a l, 1989). In the case of the 
progesterone receptor two regions have been identified for nuclear localisation: one is 
located around position 638-642 and acts in the absence of hormone. The second is 
located in the steroid binding domain and has very little activity.
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2.1.4 Steroid Receptor Comparative Anatomy
Early protein chemical studies of the steroid hormone receptor suggested that they 
are structurally organised into different domains (Wrangler and Gustaffson 1978; 
Carlstedt-Duke et al., 1982; Wrange et al., 1984; Carlstedt-Duke et al., 1987). In 
recent years the results of cDNA cloning of all the major steroid hormone receptors 
and comparing the deduced amino acid sequence has confirmed this prediction. All 
receptors thus far analysed are structurally organised into six regions of varying 
homology denoted A to F (see Figure 3) (Krust et al., 1986). The two most highly 
conserved regions are C and E which correspond to DNA and ligand binding domains 
(Evans, 1988). The N-terminal region is variable, and is less well characterised but 
may have a modulatory effect on transactivation.
The high degree of conserved regions within the cDNA steroid receptor sequences 
led to the isolation of additional receptor genes. Screening genomic libraries with 
cDNA under low stringency hybridisation has identified sequences encoding receptors 
including oncogenes such as v-erb A. It is striking that the hormone family should 
evolve into a group of receptors that are capable of binding such a wide variety of 
biologically unrelated ligands.
A comparison of receptor structure and function indicates that the steroid receptor 
family can be divided into two subfamilies: one including the glucocorticoid, 
progesterone, androgen and mineralocorticoid receptors and the other including 
oestrogen, thyroid hormone, retinoic acid and vitamin D3 receptors. Within each 
subgroup the primary amino acid sequence of the DNA binding domain is much more 
closely conserved. However, the existence of two subgroups would make it 
conceivable that a further divergence occurred early in the evolution of the steroid 
receptor family.
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Transactivation DNA-binding Hormone binding 
Dimerization 
Transactivation 
90k hsp binding 
Nuclear Localisation
Nuclear Localisation
(a sequence im mediately adjacent 
to th e  C-terminal zinc finger)
Figure 3. General structural and functional organisation of hormone receptors proteins.
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2.1.5 Steroid Receptor Activation
Historically, steroid receptors were found in at least two distinctive forms. The first 
is a large heteromeric complex consisting of steroid-binding and non-steroid binding 
subunits with a sedimentation coefficient of 8-10S and was originally extracted in low 
ionic strength buffers. The second is a smaller unit consisting only of the steroid 
receptor and bound hormone which has a sedimentation coefficient of 4-5 S, (Baulieu,
1987) and was originally extracted from the nuclear pellet using high (0.6M) salt. The 
8-10S complex is unable to bind to DNA and has correspondingly been termed 
"nonactivated''. Via the mechanisms referred to as "activation" and "transformation" 
the 8-10S complex can be converted into the 4-5S unit which can bind DNA and 
accordingly is termed "activated" (Grody et al., 1982; Sakai and Gorski, 1984). There 
is some bimodal usage of the terms activation and transformation, however, in the 
case of the oestrogen receptor and perhaps others, these represent separate processes 
(Muller et al., 1983). Receptor-activation can be defined as a dissociation of the non­
steroid binding subunits from the 8-10S complexes producing a DNA binding receptor 
(Puri and Toft 1984). Whereas transformation of the oestrogen receptor is seen as a 
further increase from 4S to 5S to produce an oestrogen receptor species 
demonstrating slower oestrogen dissociation kinetics (Muller et al., 1983). Further 
cross linking studies (Muller et al., 1983) suggest that this 5S form of oestrogen 
receptor consists of a dimer of two steroid-binding subunits.
The inactive 8-10S complex is maintained by an association of the receptor with 
other proteins. There are several fairly clear examples of receptor associated proteins, 
one of which is the 90Kheat shock protein. Clarification of a receptor: hsp90 complex 
was provided by several approaches: metabolic labelling studies (Howard and 
Distelhorst, 1988), yeast mutants (Picard et al., 1990) and chemical cross linking 
experiments (Rexin et al., 1992). However, while a role of hsp90 receptor state is 
strongly supported its function remains unclear. With the glucocorticoid receptor, 
hsp90 binding seems to be required for strong ligand activity, but once hormone
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binding has occurred, it can be sustained without hsp90 (Bresnick et al., 1989; 
Nemoto et al., 1990). This dependence, however, is not a universal relationship. The 
androgen, oestrogen and progesterone receptors do not require hsp90 for ligand 
binding activity. Though hsp90 dimers are part of the 8-1 OS "inactive" complex and 
may be involved in masking the DNA binding domain until such times as the receptor 
is activated through ligand binding.
None of the receptor associated proteins so far known are unique to a single 
receptor or cell type; they all appear to be common cellular proteins that are much 
more abundant than steroid receptors. For example the ER-related protein hsp-27, 
appears to be a component of the oestrogen response machinery (King and Coffer, 
1988) and is possibly a component of other steroid receptors. Therefore, the 
association of these proteins with steroid receptors may reflect their general function 
within a cell. One role often proposed is the efficient maintenance of inactive receptor 
unable to bind DNA without ligand. They might also serve to inhibit receptor 
degradation. Other possible functions include, aiding polypeptide chain folding, 
nuclear translocation, and molecular interactions with other cell signalling systems.
2.1.6 The DNA-Binding Domains Of Steroid Receptors
All steroid receptors analysed contain a cysteine and basic amino acid rich, highly 
conserved core of 66-68 amino acids (Evans, 1988). Green and Chambon conclusively 
demonstrated that this region was the DNA binding domain by creating a chimaeric 
receptor (Green and Chambon, 1987). By replacing this 66-amino acid region of the 
oestrogen receptor with that from the glucocorticoid receptor, they demonstrated the 
oestrogen induction of a glucocorticod inducible gene. The amino acid sequence of 
this region indicated that there are present two zinc-stabilised peptide loop structures. 
They are commonly referred to as "zinc fingers" and bind to the major groove of the 
DNA (see Figure 4) (Weinberger et al., 1985; Danielson et al., 1986, Evans and 
Hollenberg, 1988). This type of region has been shown to exist in a
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Fig. 4. Comparisons between TF1HA related transcription factor zinc finger and 
steroid receptor zinc finger. The 'zinc finger1 motif of TFIIA related 
transcription factors are defined by four metal ligands arranged cys x. -cys x. - 
His x. -His and three conserved hydrophobic residues. The steroid hormone 
receptors metal ligands are exclusively cysteine residues, but the spacing 
between these is similar to that in the ITlllA related transcription factors.
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number of DNA binding proteins and is similar to the folding scheme for the series of 
nine tandemly repeated sequences found in transcription factor IDA (TFIDA). 
However, TFIDA forms its zinc fingers by binding a zinc atom with two cysteine and 
two histidine residues while the hormone receptors bind a zinc atom through 4 
cysteine residues. Positive identification of the finger structures co-ordinated by 
cysteines was reported by Freedman and co-workers for the glucocorticoid receptor 
using EXAFS spectroscopy(Freedman et al .,1988). Two complexes of the 
glucocorticoid receptor DNA binding domains with two oligonucleotides, differing 
only in their half-site spacing were characterized using x-ray crystallography (Luisi et 
al., 1991) The loop of the zinc finger consists of between 12 to 13 amino acids and 
the two fingers are linked by a region of 15-17 amino acids (Umesono et al., 1989). 
Each finger is believed to have different fimction; the first has been demonstrated to be 
primarily responsible for determining target specificity (Green et al., 1988). The 
second finger is important for nuclear localisation and probably stabilises the DNA 
receptor interaction (Picard et al., 1987).
2.1.7 Hormone Response Elements
Steroid hormone receptors transduce extracellular hormonal signals to target genes 
by their interaction with specific enhancer gene sequences that are referred to as 
hormone response elements (HRE) (Evans, 1988; Green et al., 1988). Each receptor 
recognises its own HRE, ensuring that a distinctive response is triggered by different 
hormones. The HRE's are cis-acting and they fimction in a relative orientation and 
position independent manner. Structurally they are related, but functionally they are 
not. Several reponse elements have been characterised. These include glucocorticoid 
response elements (GRE), oestrogen response elements (ERE) and thyroid response 
element (TRE) (see Figure 5).
HRE’s are organised into palindromic pairs of hexameric "half-sites". The half sites 
can differ in sequence, for example two nucleotides per half site differ between GRE
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GRE AGAACA xxx TGTTCT
ERE AGGTCA xxx TGACC
TRE AGGTCATGACCT
Fig. 5 Comparison of symmetrical DNA response elements. The DNA-binding sites 
of the glucocorticoid (GRE), oestrogen (ERE), and thyroid (TRE) hormone 
receptors are shown. The GRE and ERE differ only in two base-pairs in each 
half site. In contrast, the TRE differs from the ERE in the spacing of the two 
half sites.
25
and ERE (Klock et al, 1987) or by the spacing between these sites. TRE and ERE 
have identical half-sites but differ in their spacing. Therefore, HRE's can diverge by at 
least two means.
Interestingly, GRE's are typically used not only as glucocorticoid response 
elements but also as progesterone, androgen and mineralocorticoid response elements, 
as shown by transcriptional regulatory studies involving these respective receptors 
(Stahle e/tf/., 1987; Darbre e ta l, 1986; Cato e ta l, 1987; Ham and Parker, 1988; 
Cato and Weihmann, 1988). The oestrogen response element is distinct but closely 
related to the GRE. In fact only 2bp mutations in both arms of the palindrome is 
sufficient to convert it to a GRE (Schutz, 1988; Martinez et al., 1987).
2.1.8 DNA Binding Receptor Dimers
Because of the palindromic nature of HRE sequences it has been suggested that 
hormone receptors can bind to DNA as asymmetrical dimers. Activated GR can form 
either a homodimer or can be detected as a monomer in solution, absent of DNA 
(Eriksson et al., 1990). The formation of oestrogen dimers has also been reported 
(Kumar and Chambon, 1988). The GR binds as a dimer to it's HRE (Perlman et al., 
1990). This clearly suggests that an equilibrium exists between GR monomer and 
dimer and that the GR could bind to the GRE by one of 2 possible mechanisms. Either 
in a stepwise manner, where a monomer binds to one half-site and strong positive 
cooperativity results in the binding of the second monomer or as a preformed dimer 
binding to the HRE.
Kumar and Chambon first showed that the dimerisation of the oestrogen receptor 
is principally linked to a region within the ligand binding domain (Kumar and 
Chambon, 1988). Using deletion and site-directed mutagenesis techniques, the 
dimerisation domain has been sublocalised to the ER residues between 500-540 
(Farwell et al, 1990). Comparisons with other members of the receptor superfamily, 
has detected a heptad repeat of hydrophobic amino acids that could possibly form a
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dimerisation interface. Coiled-coil interactions between monomers could conceivably 
take place within this region allowing for the possibility of homo and heterodimers 
forming. Receptors containing the hormone binding domain form a more stable 
complex with the DNA.
Recent studies indicate that the PR exists preferentially in the dimer state and 
direct analysis of cPR dimerisation has revealed that this process is hormone 
independent (Rodriguez et al, 1990). However, as yet no dimerisation motif has been 
found within the PR structure. Due to the PR's somewhat unusual ability, among the 
steroid hormone class of receptors, to synthesise two different sized polypeptides, 
analysis has revealed that the PR can bind to the PRE as one of three possible dimeric 
species, as two homodimer states and as a heterodimer state (Rodriguez et al., 1990; 
DeMarzo et al., 1991). The ability of the PR to form three dimeric species may 
provide a mechanism by which receptor molecules with different functional activities 
could be created. Also the preferential formation of dimers by the PR raises the 
possibility that the heat shock protein/inactivated steroid receptor complex may inhibit 
receptor DNA binding indirectly by blocking dimerisation.
2.1.9 The Hinge Region
The DNA binding domain and hormone binding domains are linked by a group of 
hydrophilic amino acids which are conserved neither in sequence nor in length among 
the different steroid receptors. There is, however, poor conservation among the ER 
from different species (Krust et al., 1986; Koike et al., 1987; Weiler et al., 1987).
This sequence of amino acids is referred to as a region D within the functional 
domains of steroid receptors. Region D is believed to act as a "molecular hinge" 
between the DNA binding domain and the hormone-binding domains during steroid 
receptor conformational changes (Kumar et a l, 1986). Mutagenesis analysis of this 
region demonstrates that a functional receptor does not require this region to adopt a 
precise structure (Kumar et a l, 1987).
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2.2 Transcription Activation
Steroid receptors bind to specific DNA sequences ultimately eliciting specific 
effects at the transcription level. Transactivation occurs when defined regions of the 
steroid receptor molecule combine with the DNA binding activity to produce an 
increase in transcriptional activity. Using deletion mutants and chimeric receptor 
constructs it has been demonstrated, in PR, GR and ER, that there exist two domains 
responsible for the transcriptional activation of target genes (Tora et al., 1989; 
Webster et al., 1988; Meyer et al., 1990). The two autonomous transcription 
activation functions (TAFs) are located, TAF-1 at the N-terminal region of the 
receptor, and TAF-2 within the hormone binding domain. The nature of the two TAFs 
in either ER and PR is unclear.
Initial investigations into the location and the number of TAFs within steroid 
receptors produced apparently contradictory results (Gronemeyer et al., 1987; Kumar 
et al., 1986; Godowski et al., 1986). However, systematic studies of the discrepancies 
observed between different groups are explained by differing parameters in the various 
experimental protocols (Bocquel et al., 1989). Thus it was demonstrated that the two 
TAFs could indeed be observed in both the PR and GR when transfection experiments 
were performed in Hela cells. The subsequent experiments revealed that the hormone 
binding domains of both the glucocorticoid and progesterone receptor has a repressor 
type fimction in the absence of the ligand. Also the relative fimction of each TAF was 
shown to be possibly related to cell specificity. Further studies demonstrated that the 
transcriptional action by TAF-2 in the ER is strongly dependent upon the promoter 
content. While the activity of TAF-1 is in general less affected by such variations 
(Berry et al., 1990; Tora et al., 1989).
Cell specific transcriptional activation by steroid receptor is thought not to be 
limited to specific domains within the steroid receptor but that the presence of
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intermediary factors may be necessary. Such protein-protein contacts could occur with 
either the tata box or even the RNA polymerase II (Ham et al., 1988). Additionally, 
the introduction of further steps to the nuclear receptor signal transduction pathway 
could add further combinational possibilities for regulation of transcription of the 
target gene.
2.2.1 Receptor Phosphorylation
Both enzymatic and non-enzymatic proteins can be regulated by the activities of 
reversible covalent modifications. Protein phosphorylation-dephosphorylation is a 
major regulatory process of cellular activity that is controlled by protein kinase and by 
phosphoprotein phosphatase (Cohen, 1982). All the steroid receptors that have been 
tested have been found to be phosphoproteins, yet the functional role for steroid 
receptor phosphorylation/dephosphorylation remains poorly defined. Attempts have 
been made to link phosphorylation to hormone (Mendal et al., 1987) and receptor 
turnover and processing (Horwitz and McGuire, 1978). Hormone binding of crude 
androgen receptor has been shown to be increased by ATP (Goueli et al., 1984). 
Purified calf intestinal alkaline phosphatase has been shown to inactivate 
glucocorticoid binding to the glucocorticoid receptor (Nrelson et al., 1977).
Phosphopeptide-mapping studies with different progesterone receptor sources has 
indicated the presence of multiple phosphorylation sites. Predominately on serine 
residues (Moudgil, 1990; Sheridan et al., 1989; Sullivan et al., 1988) and this has been 
confirmed by the identification of some of those sites by amino acid sequencing 
(Bodwell et al., 1991). The time at which progesterone receptor phosphorylation 
occurs is thought to be via a multi-step process that raises the possibility that different 
enzymes may phosphorylate different sites, potentially serving different functions. 
Initial phosphorylation is thought to occur at the basal level, as a post-translational 
modification occurring as the receptor matures (Sheridan et al., 1989). This 
nonactivated form of progesterone receptor becomes complexed with at least two heat
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shock proteins, hsp90 and hsp70 (DeMarzo et al., 1991; Kost et al., 1989; Pratt et al., 
1990). Once progesterone binds to the progesterone receptor a further round of 
phosphorylation occurs, possibly decreasing the receptor's affinity for the multiprotein 
complex. Addition of progestins has been shown to generate hyperphosphorylated 
forms of the receptor within 5 mins of binding (Sullivan et al., 1988). A third stage of 
phosphorylation occurs after the progesterone receptor has tightly bound to the DNA. 
This further act of hyperphosphorylation has been postulated to be complete receptor 
transformation and facilitate appropriate protein-protein interactions promoting 
transcription (Takimoto et al., 1992). The steps cited above maybe incomplete.
Further stages may occur during a steady progression of phosphorylation rather than 
set intervals once progestins are bound.
At present the format by which oestrogen receptors are phosphorylated is 
undetermined and is of need of resolution. A great deal of evidence has been provided 
over the preceding decade by Auricchio, Migliaccio and co-workers to suggest that 
the oestrogen receptor is regulated via a tyrosine phosphorylation systems (Auricchio 
et al., 1990). Experiments using cell free systems suggest that a nuclear phosphatase 
inactivates the steroid binding capacity of oestrogen receptors and that a cytosolic 
kinase under the influence of Ca+^-calmodulin (Migiliaccio et al., 1986) restores this 
activity by phosphorylating tyrosines. Antibodies directed against phosphotyrosine 
were used to demonstrate that tyrosine phosphorylation also occurs in vivo, a reaction 
that was abolished by treatment with nuclear phosphatase (Migilaccio et al., 1984). 
Tyrosine phosphorylation has been used to constitute newly synthesised oestrogen 
receptor to acquire ligand binding activity.
In sharp contrast with these observations but in agreement with other steroid 
hormones, it has been reported that oestrogen-stimulated phosphorylation of the 
human or calf oestrogen receptor occurred only on serine residues (Denton et al.,
1992; Washburn et al., 1991). In addition studies of phosphorylation of oestrogen 
receptors in chicken oviduct and mouse uterine cells indicate 
phosphorylation/dephosphorylation of serine residues (Washburn et al., 1991).
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Although it is established that the oestrogen receptor is a phosphoprotein it is still 
necessary to determine which residues are phosphorylated in vivo, whether 
tyrosine/serine or both, which proteins mediate site specific phosphorylation and 
dephosphorylation, and the role it plays in receptor regulation.
General aspects of receptor phosphorylation are beginning to emerge. The receptors 
are basally phosphorylated in the unliganded form They become hyperphosphorylated 
after association with hormone (Sheridan et al., 1989; Sullivan et al., 1988; Sheridan 
et al., 1988). Residues that are phosphorylated have been identified on the chick 
progesterone (Bodwell et al., 1991) and mouse glucocorticoid receptors (Denner et 
al, 1990), most he in the N-terminal domain. Almost ah studies so far conducted 
point to serine as the main phosphorylated amino acid with minor amounts of 
threonine (Moudgil, 1990; Sheridan et al., 1989; Hoeck and Groner, 1990; Sullivan et 
al., 1988). The notable exception is the oestrogen receptor, where physiological 
phosphorylation of tyrosine residues takes place (Migliaccio et al., 1986).
2.2.2 Regulation of Receptor Synthesis
Regulation of functional protein synthesis can occur at every stage of its 
production. From the regulation of initiation of gene expression to post-translational 
modifications. Both oestrogen and progesterone receptor levels in target tissues 
appear to be under dual hormone control (see Figure 6). Oestrogens have long been 
recognised as an important regulator of the intracellular content of the progesterone 
receptor (Clark et al., 1971). It is almost certain that an oestrogen hormone response 
element exists 5' to the progesterone receptor gene (Ree et al., 1989). Breast epithelial 
cells grown without oestradiol generally have only low basal levels of progesterone 
receptor. The notable exception being the cell-line T47D which has high PR protein 
and RNA levels independent of oestradiol (Berkenstam et al., 1989). The T47D cells 
probably contain a duplication of chromosome 11 increasing the PR gene copy
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number (Horwitz et al., 1985; Law et al., 1987). This, however, does not explain the 
oestrogen independence. In most PR positive cell lines, exposure of cells to 
oestrogens causes PR levels to rise and are maintained at new, elevated steady state 
levels (Horwitz et al., 1978). Withdrawal of oestrogens in the absence of progestins 
results in a primary rapid decay with a half-life of approximately 2 days, followed by a 
secondary decay of 21 days. The half-life of empty PR in MCF-7 cells has been shown 
using dense amino acid containing medium to be approximately 28 hrs (Nardulli et al.,
1988). This value is identical in cells in which maximal or half-maximal levels of PR 
are maintained. Therefore, the increase in cellular PR during oestrogen exposure is not 
due to a slowing of receptor degradation.
In contrast to oestrogen exposure progestins decrease progesterone receptor 
levels in target tissues. Using density shift techniques it has been determined that 
unoccupied PR in the human breast cell-line T47D has a half life of 21 hrs (Nardulli et 
al., 1988). However, in the presence of the synthetic progestin, R5020, receptor half 
life has been shown to be reduced to only 6 hrs. Besides an increase in receptor 
degradation, receptor synthesis was also shown to be markedly decreased. After 30 
hrs of maintained exposure of cells to 20nM R5020, no newly synthesised receptor 
was subsequently detectable on sucrose gradients (Nardulli et al., 1988). Clearly 
progestin exposure causes dramatic reductions in the level of the receptor present, the 
extent and the time course of receptor decline being dependent upon the concentration 
of the progestin. Low levels of progestins reduce receptor levels by a smaller 
percentage over a longer duration than would high concentrations. Replenishment 
rates are dependent upon the rate at which each progestin is metabolised by cells. 
Progesterone is rapidly metabolised by cells (half-life approximately 4 hrs) while 
synthetic progestins e.g. R5020 can take much longer to be metabolised. Evidence 
also exists that progestins down regulate PR mRNA through transcriptional inhibition 
(Wei e ta l, 1988).
The effects of ligand on receptor turnover has been noted in other systems as well. 
The presence of ligand has been shown to be involved in the homologous down
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regulation of thyroid and glucocorticoid receptor by increasing their rates of 
degradation (Raaka and Samuals, 1987; Rosewicz et al., 1988). In contrast the 
presence of ligand upon the androgen receptor elicits a decrease in degradation rate 
resulting in increased receptor accumulation (Syms et a l, 1985).
Progestins have long been known to act as an antiestrogens in terms of growth 
regulation of both normal and cancer cells in vitro (Katzenellenbogen, 1980). It is 
possible that this inhibitory effect is caused, in part, by suppression of E2- elicited up 
regulation. It has been reported that progestins used on MCF-7 and T47D cell-lines 
down regulate the oestrogen receptor (Berkenstam et al., 1989). In T47D cells the 
addition of the progestin R5020 causes ER message levels to be reduced to 
approximately 20% of control levels within 2 days of exposure. A reduction in ER 
protein by progesterone has also been documented in rat uterine (Bhakoo and 
Katzenellenbogen, 1977) and in hamster uterine cells (MacDonald et al., 1982).
Amino acid incorporation density shift experiments have revealed that decidual cells 
treated with oestrogen plus progesterone elicit a shortened oestrogen receptor half-life 
and have indicated that progesterone blocks E2- induced ER protein synthesis in these 
cells (Bahkoo and Katzenellen, 1977; Takeda et a l, 1986).
In MCF-7 and T47D cells, it has been shown that oestrogen binding to receptor 
results in the down regulation of oestrogen binding sites (Berkenstam et al., 1989; 
Horwitz et al., 1982). The decline in receptor protein to a new steady state level is 
accompanied by a parallel decreased in the level receptor mRNA (Saceda et al.,
1988). In sharp contrast to PR, the turnover of the ER with a half-life of 2.5-4.5 hr is 
the same in the presence or absence of oestrogen (Eckert et al., 1984; Scholl et a l, 
1984). Evidence would suggest that the level of mRNA is regulated almost exclusively 
by a post-transcriptional event (Brock and Shapiro, 1983; Saceda et a l, 1989). Both 
nuclear and cytoplasmic mRNA levels are suppressed when cells are exposed to 
oestrogens suggesting that the post-transcription suppression of the receptor is a 
nuclear event (Seceda et al., 1989). Furthermore, it has been demonstrated that 
certain antiestrogen compounds have no effect on the level of ER mRNA and
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effectively block the effect of oestradiol on ER mRNA levels. This would strongly 
suggest that the classical ER plays a key role in the post transcription regulation of ER 
mRNA. Inhibition of protein synthesis using cycloheximide has no effect on the 
suppression of ER mRNA when exposed to oestrogens in MCF-7 cells, at least in a 6 
hrs-inhibition (Seceda et al., 1989). This would suggest that the oestrogen-induced, 
ER mediated effect on the receptor mRNA level, is independent of protein 
biosynthesis. Steroid hormone receptors have been reported to form complexes with 
RNA (Chang et al., 1982). Although data suggest that the effect of oestradiol on the 
level of receptor mRNA is a primary effect of the ER, other possibilities cannot be 
ruled out such as: the oestrogen receptor mediated effect is through the induction of 
an RNA species.
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Dual Regulation of Oestrogen and Progesterone Receptor Levels
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Fig. 6 A model for the dual regulation of oestrogen and progesterone receptor 
levels. Activated oestrogen receptor binds to the oestrogen hormone response element 
5' to the progesterone receptor gene initiating progesterone receptor synthesis. Newly 
synthesised progesterone receptor hinds progesterone causing dramatic reductions in 
the level of the progesterone receptor. Active progesterone receptor down regulates 
the oestrogen receptor. In the absence, or at pharmacological concentrations of 
oestrogens, the oestrogen receptor is down regulated.
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3 STEROID RECEPTORS IN 
ENDOCRINE MANAGEMENT
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3.1 Endocrine Management Of Breast
Treatment of primary breast cancer usually involves the surgical removal of all 
clinically apparent disease. However, it is well established that subclinical metastases 
are often present before clinical detection of the primary cancer. Therefore, following 
surgery, appropriate adjuvant systemic treatments such as radiotherapy and 
chemotherapy are considered. A comprehensive description of these treatments is not 
within the scope of this thesis, but improved endocrine therapy is directly concerned 
with this research.
Endocrine therapy is based on the idea that certain tumour cells retain their 
sensitivity to hormones that regulate function and growth of their normal progenitor 
cells. Oestrogen is a highly potent mitogenic agent in the normal mammary gland. 
Endocrine therapy must therefore, aim to negate or even reverse the proliferative 
effects of oestrogens or other influential hormones. This goal can be achieved in a 
significant number of patients using either ablative or additive hormone therapy.
Approximately two thirds of all breast cancer patients will not respond to 
endocrine therapy. However, it has been observed that tumours containing ER and/or 
PR are more likely to respond to this treatment (Souter and Leake, 1987) : 60% of 
patients with oestrogen receptor positive tumours and up to 75% of patients with both 
ER and PR will respond. PR being taken as a measure of active ER The measurement 
of steroid receptors can therefore assist physicians in the selection of a treatment for a 
patient which will provide the best response.
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3.2 Ablative Hormone Therapy.
Ablative hormonal therapy is the surgical removal of endocrine organs which are 
the major sources of oestrogens or their precursors, as adrenalectomy and 
hyophysectomy in post-menopausal or oophorectomy in pre-menopausal patients. 
Adrenalectomy and hypophysectomy are seldom practised today, since they carry 
large surgical risks and major secondary side-effects. However, for premenopausal 
women oophorectomy is still commonly performed either by surgical or radiation 
methods, resulting in reponse rates of 31% in non-selected patients (Kardinal 1988). 
This response rate can be increased to 55% by selecting ER positive patients and to 
78% by selecting ER and PR positive patients.
3.3 Adjuvant Therapy
On the assumption that many patients with primary disease may already have 
micro-metastatic deposits, many studies have been set up to establish whether 
systemic therapy, given after first surgery, can result in prolonged survival. All eligible 
studies have recently been the subject of an overview (Peto, 1992). The general 
conclusion is that adjuvant chemotherapy is a significant advantage for premenopausal 
patients as is adjuvant endocrine therapy for post-menopausal patients.
3.4 Antiestrogens
Antiestrogen therapy is the hormonal therapy most commonly used to treat breast 
cancer. Clinically used antiestrogens such as Tamoxifen are referred to as steroid 
antagonists. Antiestrogens bind to the oestrogen receptor and if present at sufficient 
concentrations they competitively inhibit the binding of oestrogens, inhibiting their 
biological activity (Berry et al, 1990). Several studies have found that these steroid 
antagonists induce changes in the oestrogen receptor that can influence its
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physiochemical responses (Rochefort and Borgnal, 1981; Sasson, and Notides, 1982; 
Pavlik et al, 1985; Pavik et al., 1986; Faye et a l , 1986; Hanson, and Gorski, 1986). 
Further studies have shown that different ligands bound to the oestrogen receptor 
elicit different conformational changes. Polyclonal antibodies raised against the 
oestrogen receptor have been shown to inhibit the binding of [^H] oestradiol but not 
[3m 4-hydroxytamoxifen (Tate et al, 1984 (a); Tate et al., 1984(b)). Furthermore, it 
has been discovered that the binding of antiestrogens to the oestrogen receptor 
exposes an antigenic determinant not recognised when oestrogens are bound (Martin 
et al., 1988). This site can be exposed even in the presence of oestradiol indicating 
that antiestrogens may interact with regions separate from the oestrogen binding site. 
In related studies, the sedimentation characteristics of ligand bound oestrogen 
receptor complexes has been shown to vary depending on the type of ligand bound, 
oestrogen or antiestrogen (Eckert and Katzenellenborg, 1982). However, Elliston and 
Katzenellenbogen found that both types of ligand bound to a similar sequence in the 
steroid receptor (Elliston and Katzenellenbogen, 1988). Therefore, the distinctive 
biological activities of oestrogens and antiestrogens cannot be attributed to different 
ligand binding sites but more than likely to subtle changes in the receptor's 
conformation.
Current research has focused upon structure-relationships of different ligand 
oestrogen receptor complexes. Antiestrogens fell into two categories each inducing a 
response by a different method. The triphenylethylene type form 
antiestrogen/oestrogen receptor complexes displaying a lesser affinity than 
oestradiol/ER complexes for target DNA (Evans, et al., 1982), and differ in their 
interactions with nuclear chromatin (Singh et al, 1986). Recently it has been found 
that 4-hydroxytamoxifen/receptor complexes bind to oestrogen response elements 
(Metzer et al., 1988). However, interestingly, the antiestrogen/receptor complexes do 
not stimulate all transcriptional events (Webster et al., 1988). Therefore, 
triphenylethylene antiestrogens may exert their response by allowing oestrogen
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Fig. 7 A Schematic Model of Antiestrogen Action in Breast Cancer Cells. This 
diagram attempts to summarise the current understanding of antiestrogen action upon 
the oestrogen receptor in terms of ligand binding, dimerisation and DNA binding.
In this simplified scheme antiestrogens bind to the oestrogen receptor. 'Pure' 
antiestrogens exert their biological activities by preventing the oestrogen receptor 
from dimerising and binding to DNA. Triphenylethylene antiestrogens allow the 
receptor to dimerise and to bind to the DNA. However, these antiestrogen/oestrogen 
receptor complexes display a lower affinity with hormone response elements and do 
not stimulate all transcriptional events.
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Schematic Model of Antiestroqen Action
in Breast Cancer Cells
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Receptor dimerisation and DNA binding but fail to stimulate transcription at either of 
the two transactivation domains (Leese et al, 1989). In contrast, pure antiestrogens 
are believed to exert their biological activities by preventing oestrogen receptor 
dimerisation and DNA binding (Fawell et al., 1990) (see Figure 7).
Oestrogens modulate the growth of breast cancer cells by inducing growth factors 
or their receptors which in turn invoke a stimulatory or mitogenic effect (Leake et al., 
1990). Alternatively antiestrogens interfere with the growth factor stimulated 
proliferation possibly by increasing the production of inhibitory growth factors and 
decreasing the production of stimulatory growth factors.
The effect of steroids upon the induction of growth factors in breast cancer is the 
subject of numerous reports. The transforming growth factors a  and J3 have readily 
been shown to be influenced by the presence or absence of oestrogens. Work by 
Lippman's group has (Bates et al, 1988) demonstrated that oestrogen stimulation of 
breast cancer cells results in the elevated secretion of TGF-a, known to stimulate 
colony formation, while decreasing the levels of growth inhibitor, TGF-(3 (Knabbe et 
al, 1987). Antiestrogen treatment reduces TGF-a secretion (Dickson et a l, 1986) 
and induces the release and activation of TGF-(3. Another potent mitogen known to be 
inhibited by antiestrogens is the insulin like growth factor-I (IGF-I). Some proto­
oncogenes have also been shown to be down regulated by antiestrogens e.g. c-myc 
(Le Roy et a l, 1991). It is probable that the known number of growth factors affected 
by antiestrogens will increase as the role of growth factors in response to hormonal 
treatments is further defined. Oestrogens and antiestrogens elicit their respective 
responses probably through their interactions with the oestrogen receptor.
It has long been recognised that the effects of antiestrogens are sometimes 
mediated through mechanisms independent of the oestrogen receptor. Work by 
Sutherland and co-workers demonstrated that radioladelled Tamoxifen will bind to an 
"antiestrogen-binding site" (AEBS), later shown to be located in the microsomal 
fraction of all tissues investigated (Sutherland etal., 1980(a); Sutherland et al, 
1980(b); Kon, 1983; Watts and Sutherland, 1986). Interest in AEBS lead to broad
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ranging investigations of antiestrogen interactions with other receptors e.g. dopamine 
D2 receptors (Hiemke et al, 1984) and histamine receptor (Kroeger et al, 1985). 
However, these receptor systems do not appear to represent the AEBS (Watts and 
Sutherland, 1987). Development of compounds that bind solely to AEBS will help in 
defining the role of the AEBS in cellular biochemistry.
Antiestrogen action is not limited to the direct site of the tumour itself. Studies 
indicate that Tamoxifen might act as a potent antiestrogen at the hypothalamo- 
pituitary axis, causing a decrease in the mid-cycle peak of prolactin but little or no 
increase in the concentrations of circulating LH and FSH in premenopausal patients 
(Groom and Griffiths, 1976; Manni et a l , 1979). However, there is an increase in 
circulation oestrogen (Sherman and Korenman, 1974). In postmenopausal patients 
Tamoxifen causes a decrease in both LH and FSH, demonstrating mild oestrogenic 
properties (Golder et a l , 1975, Golder et a l, 1976). Tamoxifen does not increase 
circulating oestradiol in postmenopausal patients.
The most commonly used clinical antiestrogen administered to postmenopausal 
breast cancer patients is Tamoxifen. In general patient populations, Tamoxifen can 
yield response rates of greater than 30% and in ER positive selective populations this 
response can go up to 60% to 75%. In randomised trials with postmenopausal 
patients, Tamoxifen has been compared with other hormonal treatments, oestrogens, 
androgens, progestins, adrenalectomy and hypophysectomy (Henderson et a l, 1987). 
The response rates for all of these therapies are not significant different, except for 
androgens that appear inferior. However, Tamoxifen is significantly less toxic. The 
most common side effects suffered by patients receiving Tamoxifen include nausea 
and worsening of hot flashes which occur in approximately in 10% of patients. Other 
less frequently occurring side effects include bone pain and hypercalcemia. Tamoxifen 
has been shown to induce ovarian steroidogenesis in premenopausal women, elevating 
oestradiol levels (Manni and Pearson, 1980; Sherman et al, 1979). Despite this, 
circulating levels of FSH and LH are unchanged from, or only slightly elevated over
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the norm. Tamoxifen has been associated with an increased incidence of fibroid 
ovaries and ovarian cysts (Powles et al., 1989).
3.5 Progestins and Antiprogestins
Progestin antagonists are relatively new compounds that have proven activity in 
the treatment of breast cancer. The precise mechanism by which both antiprogestins 
and high dose progestin agonists inhibit growth of breast cancers remains unclear. 
However, in human breast cancer cell lines high dose progestins exert a direct 
antiproliferative effect and abolish the stimulatory effect of oestradiol on growth 
(Allegra and Kiefer, 1985J. In contrast antiprogestins are antiproliferative even at low 
dose and are believed to act directly through the progesterone receptor. Investigators 
postulate that there are at least two types of antiprogestins: type 1 that block PR 
binding to PREs; and type 2 that promote PR binding to PREs but impede 
transcription, echoing a general mechanism of antagonist action proposed by 
Guiochon-matel and co-workers (Guiochon-mantel et al., 1988). Antiprogestins can 
also form filled receptor complexes which only down regulate partially, if at all, 
allowing nuclear receptor levels to remain high for hours if not for days. This is in 
sharp contrast to PR bound agonists which initiate receptor down regulation 
approximately an hour after DNA binding.
The actions of a progestin are not limited to the site of the tumour. They may 
cause oestrogen deprivation indirectly through the suppression of pituitary ACTH 
secretion resulting in reduced production of adrenal androgen precursors (Mathews et 
al., 1970). This was demonstrated by the fall in the serum levels of 11-deoxycortisol 
before and after metyrapone administration (Alexieva-Figusch et al., 1984).
Additional endocrinological effects observed with megestrol acetate administration 
include, suppression of circulating levels of oestradiol, sex hormone globulin and 
gonadotropins and an increase in basal as well as TRH stimulated plasma progesterone 
levels.
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The overall success of progestin therapy is dependent on the drug entering the 
target tissue in sufficient quantities to interact with and activate the appropriate 
numbers of receptors in each cell. Therefore, both plasma concentration of the drug 
and the blood supply to the tumour influence availability of the drug to the cancer 
tissue. Additionally, the functional progesterone receptor content of the tumour needs 
to be sufficiently high to pull in relatively small amounts of the progestin against a 
concentration gradient. A higher reponse rate to progestin therapy has been observed 
in women who are more than 5-10 years beyond the menopause (Alexieva-Figusch, et 
al., 1980; Ansfield et al., 1982). Presumably because the proportion of women with 
hormone-sensitive disease continues to increase with age.
The two most commonly used progestins that have been used regularly in clinical 
studies are medroxy-progesterone acetate (MPA) and megestrol acetate (MA). 
Chemically they differ only slightly in that megestrol has an unsaturated bond between 
carbons 6 and 7. Megestrol acetate has been found to be effective as a first line 
therapy and in several randomised trials has shown itself to have similar antitumour 
actions as Tamoxifen in postmenopausal women with advanced breast cancer. 
However, when used at conventional doses (< 500mg daily) MPA has been found to 
be less effective. This difference appears to be due to the increased solubility of MA, 
relative to MPA in terms of transport across the human intestinal mucosa. This is most 
readily demonstrated by measuring the plasma concentration of the respective drugs in 
otherwise equivalent patients.
Clinical studies of megestrol acetate indicate that high dose therapy is significantly 
superior with regard to response rate than conventional (160mg/day) dosage (Muss et 
al., 1989; Aisner et al., 1987). However, there are serious side-effects of the higher 
dosage including weight gain and increased appetite in virtually all patients. These 
symptoms are of course certainly helpful in treating women with severe weight lose 
and anorexia, secondary to the advanced stage their disease.
44
3.6 Other Modalities of therapy
As more biological information is gathered further light is shed upon the 
effectiveness of antihormones and their mode of action upon regulatory pathways.
This has or will provide endocrine treatments directed at pathways not directly related 
to antiestrogen and progestin therapy.
The oestrogen that drives the growth of a hormone sensitive breast tumours can 
be the product of adrenal or ovarian synthesis, or it can be synthesised locally. Hence, 
therapies involved in blocking oestrogens may induce inhibition of HP function, inhibit 
aromatases and inhibit oestrogen function.
3.7 Systemic Therapy
Progestins and antiestrogens are known to be effective in treating advanced 
hormone-sensitive breast cancer. However, when used individually over prolonged 
periods beyond 2 to 3 years they provide little or no benefit (Stoll, 1991) and 
continuous therapy, no matter how good the initial response, leads to drug resistance 
and relapse. Long term treatment with antiestrogens usually Tamoxifen, causes the 
levels of oestrogen receptor and progesterone receptor to fall (Crawford et al, 1987) 
and in the same way long term action of progestin results in loss of progesterone 
receptor.
There are two possible approaches to overcoming these mechanisms of resistance. 
Firstly, regimens can be designed which maintain high receptor levels. Secondly, short 
bursts of alternative endocrine therapies may delay the onset of resistance to either 
drug. An approach to the first idea is to use the effects of Tamoxifen to give a short­
term increase in PR then follow Tamoxifen with Megestrol Acetate to take advantage 
of the increased PR levels. Tamoxifen is reintroduced after a period in order to 
replenish the Megace induced fall of PR Of course, the potential success of this
45
cyclical approach also be due to the second idea, as it may delay onset of Tamoxifen 
resistance.
So far alternating treatment with Tamoxifen and Megestrol acetate (Megace) or 
medroxyprogesterone acetate have been analysed in clinical trials. A recently 
published study (Leake et al, 1992) has shown that alternating the treatment with 
Tamoxifen and Megace gives a significant advantage when compared with Tamoxifen 
alone. This observation was made in postmenopausal women with locally advanced 
breast cancer.
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4 AIMS
4. Aims
This thesis was based upon a recently published study (Leake et al., 1992) 
which demonstrated that a cycle of 2 weks of Tamoxifen, followed by three weeks of 
megestrol acetate (MA), followed by one week of nothing (wash-out) gave a 
significant survival advantage when compared with the standard treatment of 
continuous Tamoxifen. This observation was made in post-menopausal women with 
locally advanced breast cancer. The initial theory behind this study was based on the 
concept that, when a patient recieves Tamoxifen over a long time peroid, the levels of 
oestrogen receptor (ER) in her breast tumour cells become reduced. Nevertheless, 
Tamoxifen, in the short-term, induce synthesis of the progsterone receptor (through 
its agonist activities). Progestins, on the other hand suppress synthesis of the 
progesterone receptor (PR). Thus, the cycle might maintain biologically effective 
levels of both ER and PR and, therefore, prolonging the time peroid over which 
endocrine therapy is effective. Because of the success of this initial study in prolonging 
overall survival of advanced breast cancer patients, it would seem reasonable to 
extend the use of the Tamoxifen-MA cycle to a larger group of breat cancer patients. 
The only serious side-effect observed in the initial study was the appearance of vaginal 
bleeding in 14% of patients in the cycle arm (less than 1% in the Tamoxifen alone 
arm). Norethisterone (NET) is able to abolish postmenopausal vaginal bleeding in 
many cases. Thus, use of the Tamoxifen-MA cycle would become realisitic in most- 
menopausal women, if the NET can be shown to abolish the bleeding without 
influencing the Tamoxifen-induced synthesis of PR. Thus the aims of this thesis are 
to establish the fidl charateristics of Tamoxifen induction of PR, in relation to cell 
growth rates, and to test whether the sensitivity of PR induction to different levels of 
NET.
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METHODOLOGY
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Materials
REAGENT SOURCE
Anti-PPLO Agent Gibco BRL Ltd
Bradford Reagent Bio Rad Ltd
BSA Standard II Bio Rad Ltd
Charcoal (Norit A Activated) Sigma
Diethylstiboestrol Sigma
Dextran Sigma
Dethiothreitol Boehring Mannhein GmbH
DMSO Fisons
DNA (Calf Thymus) Sigma
EDTA Bio Rad Ltd
FCS Gibco BRL Ltd
HEPES Fisons
Hoeschst 33258 Sigma
ICI 182,172 Zeneca
Megestrol Acetate Bristol Myers
Norethisterone Ortho Division of Cilag Ltd
[3H] Oestradiol-170 Amersham
Oestradiol-17(3 Amersham
ORG2058 Amersham
[3H] ORG 2058 Amersham
RPMI-1640 Medium Gibco BRL Ltd
Tamoxifen Base/Nolvadex Zeneca
Trypsin Gibco BRL Ltd
All other basic chemicals were purchased from BDH.
All plasticware for use in cell culture was supplied by NUNC.
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1. Buffers and Solutions
1.1 Buffers.
1.1.1 ETN Buffer
lOmM EDTA; lOmM Tris-HCl; lOOmM Sodium Chloride; pH 7.0
1.1.2 Hank's Modified Buffer
1.3mM Calcium Chloride; 5.4mM Potassium Chloride; 0.5 mM Magnesium 
Chloride, 0.5mM Magnesium Sulphate; 137mM Sodium Chloride; 4mM Sodium 
Hydrogen Carbonate; 0.4mM Sodium Dihydrogen Orthophosphate; pH 7.2-7.4
1.1.3 Dextran Coated Charcoal For Dialysis
lOOmls sterile PBS-A; 0.25% w/v Norit A charcoal; 0.0025% w/v Dextran.
1.2 Cell Culture Solutions
1.2.1 PBS-A
170mM NaCl; ImM Na2HP04; 2mM KH2P04; pH 7.2
1.2.2 Versene Solution
125mM NaCl; 2.7mM KC1; 6.3mM Na2HP04; 3.2mM KH2P04 and 0.5mM EDTA 
adjusted to pH 7.4 using HC1.
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1.2.3 Dialysed Heat Inactivated Dextran Coated Charcoal Stripped Serum
lOOmls of FCS was dialysed against 4x llitre changes of Hank’s modified buffer 
over 48hrs at 4°C. Following dialysis the serum was transferred to a glass container 
and heat inactivated for 45mins at 56°C. The serum was then cooled to 4°C before 
being added to a pellet of dextran coated charcoal. This solution was allowed to stir at 
4°C for 30mins before centrifuging at lOOOOg for 30mins at 4°C. The supernatant was 
filtered through 0.2 micron filters.
1.3 Receptor Assay Solutions
1.3.1 HE Buffer
20mM Hepes; 1.5mM EDTA; pH 7.5
1.3.2 HED Buffer
20mM HEPES; 1.5mM EDTA; 0.25mM dithiothreitol (DTT); made in a 15% 
glycerol solution; pH 7.5
1.3.3 Dextran Coated Charcoal
0.15% w/v Norit A charcoal, 0.0015% w/v dextran T70 in 0.25M sucrose; 1.5mM 
EDTA; 20mM HEPES; pH 7.4
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2. Cell Culture Methods
2.1 Cell Lines
Two established human breast cell lines were used: ZR-75-1 and MCF-7. The ZR- 
75-1 cells are derived from the malignant ascitic effusion of a metastic breast tumour 
(Engel et al .,1978) and have a doubling time of approximately 14 hours. MCF-7 is a 
stable epithelioid cell line originally obtained from the pleural effusion of a female 
patient with breast cancer whose disease responded to endocrine therapy (Horwitz et 
a l ., 1975) and has a doubling time of approximately 22 hours. Both cell lines are 
oestrogen receptor and progesterone receptor positive and were maintained in RPMI 
media, 10% foetal calf serum (FCS) at 37°C in a 5% C02 atmosphere.
2.2 Routine Cell Culture
2.2.1 Culture Conditions
Both cell lines were routinely subcultured using RPMI 1640 media with L- 
Glutamine supplemented with 10% foetal calf serum (FCS), penicillin (100 
iu/ml)/streptomycin (100 pg/ml) and Anti-pseudo pneumonia-like organism agent 
(Anti-PPLO agent) (30 jig/ml). Cell medium was changed every two to three days.
The majority of routine subculture was carried out using phenol red free RPMI -1640 
supplied as a powder, reconstituted as per manufacturers instructions.
Supplementation was as above except for FCS which was heat inactivated, dextran 
coated charcoal-stripped, dialysed FCS (HIDCCFCS) and used as 5% during hormone 
experiments. Stocks of cells were grown routinely in 175cm^ plastic tissue culture 
flasks seeded at a concentration of 4X10^ cells per flask in 25 mis RPMI 1640 and 
10% FCS. Experiments used 6 well plates seeded at a cell density of 4X10^ cells per
54
well or 24 well plates seeded at a cell density of 1.7-2.5 x10^ cells per well or 
175cm^ plates (as indicated in the text). Cells were subcultured when the substrate 
surface area was estimated to be 80-90% confluent.
2.2.2 Drugs and Hormone Supplements Used
Drugs and hormones were dissolved in absolute alcohol to form stock solutions. 
These solutions could then be added aseptically to phenol red free RPMI 1640 media 
providing working solutions of minimal alcohol content (never > 1%). (See individual 
protocols for details of the ligands used and concentrations).
2.3 Management Of Cell Lines
2.3.1 Crvopreservation of Cell lines
Whenever possible frozen stocks of MCF-7 and ZR-75-1 cells were prepared as 
followed: cells were grown in 175cm^ flasks in RPMI 1640 media + 10% FCS until 
80-90% confluent. The cells were washed and harvested as described in routine cell 
culture. The cell suspension was transferred to a sterile universal, centrifuged at lOOOg 
for 2 mins at 4°C and resuspended in 1ml 90% FCS + 10% DMSO per flask. The cell 
suspension was transferred to sterile "Biofreeze" vials and frozen overnight at -70°C 
before ultimate long term storage under liquid nitrogen.
2.3.2 Recovery of Frozen Cells
Cells were recovered from the -170°C freezer, thawed rapidly and transferred to a 
75 cm^ flask containing lOOmls of prewarmed medium (RPMI 1640 + 10% FCS) and 
incubated at 37°C. After 24hrs the cells were washed and fed with fresh medium.
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3. DNA and Protein Assays
3.1 Hoechst DNA Assay
3.1.1 Assay Principle
The method used was modified from the original Leake and Habib (1987) 
protocol. This assay is dependent upon the intercalation of Hoechst dye with 
solubilised DNA; the resulting complex is fluorescent with a maximum emission at 
450nm
3.1.2 Assay Protocol
Samples were solubilised by incubating for 30mins at 37°C in 0.1% SDS in ETN 
buffer. 100pi aliquots of each solubilised specimen were transferred to RT-30 test- 
tubes to which 3 mis of ETN containing Hoechst 33258 (lOOng/ml) and RNase (5.0 
pg/ml) were added. The tubes were vortexed and incubated at room temperature for 
30mins. The fluorescence enhancement at 450 nm was then measured using a Hitachi 
Perkin-Elmer MPF-2A fluorescent spectrophotometer with an excitation wavelength 
of 360nm and both slit widths at 5mm The results obtained were compared against a 
standard curve range of calf thymus DNA ofO, 5, 10, 15, 20, 25, 30, 40, 50 pg/ml.
3.2 Bradford Protein Assay
3.2.1 Assay Principle
This assay is based on the principle that the absorbance maximum for an acidic 
solution of Coomassie Brilliant blue G-250 shifts from 465nm to 595nm when binding 
to protein occurs (Bradford, 1976).
3.2.2 Assay Protocol
The Bradford assay reagent was diluted 1:5 with distilled water and filtered. 100 pi 
of each sample to be assayed was placed in a 10ml glass test-tube to which 5mls of 
dilute Bradford reagent was added. The tubes were incubated on ice for 5 mins and
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the absorbance of each solution measured at 595nm Where necessary the sample was 
diluted to within the range of the assay. Protein concentration was read against a 
standard curve made using bovine serum albumin (BSA) at 20, 40, 60, 80, 100, 120, 
140, 200 (tg/ml of protein.
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4. Steroid Receptor Assays
4.1 Ligand Binding Assays
4.1.1 Assay Principle
These assays can determine the total specific steroid receptors in a variety of tissues 
and cell monolayers (Leake, 1981). The calculations of Scatchard (Scatchard, 1949) 
are the basis of this principle: cytosol and nuclear samples are incubated over a 
concentration range of radioactive hormone with or without a 100-fold excess of 
unlabelled hormone to determine specific receptor binding. The soluble hormone- 
receptor complex can be separated from any free hormone in the cytosol fraction 
using dextran coated charcoal (DCC) to which free steroid is absorbed whereas 
receptor-steroid complexes are not. Hormone receptor complexes tightly bound to the 
nuclear fractions are separated from any free hormone by passing the suspension 
through a filter to which free steroid passes through freely whereas DNA receptor- 
steroid complexes cannot.
4.1.2 Ligand Binding Assay (LBA) Protocol
Cell monolayers were grown in 175cm2 flasks until 80% confluent. The cells were 
washed twice with PBS-A, harvested with a rubber policeman after the addition of 
2mls of HED buffer to the flask. The cell suspension was transferred to a sterile 
universal and cells lysis occurred by fast freezing for 5mins in -70°C freezer, followed 
by fast thawing at 37°C for lOmins. The sample was checked by microscope for 
>95% lysis before centrifuging at lOOOg for 5mins. The nuclear pellet was 
resuspended in 2mis of HED buffer while the cytostolic supernatant was spun at 
18,000 rpm at 4°C for 30 mins, removing the membrane fraction. 150(ul aliquots of 
each suspension was added to 50(j,l of each steroid radioactive standard. Each 
suspension was incubated for 18hrs at 4°C (overnight) to allow steroid binding to 
take place.
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4.1.3 Analysis of the Cvtostolic Fraction
After incubation, to each cytosol suspension, 200p,l of DCC and HED was added, 
to remove unliganded steroid. This treatment continued on ice for 15min, vortexing 
twice during this period, before centrifuging for 5mins at lOOOg to pellet the DCC 
absorbed steroid. 200pl aliquots of each suspension were transferred to scintillation 
vials to which 4mls of Ecoscint A was added. The vials were counted for tritium each 
for lmin and the cpm used to carry out computerised scatchard calculations.
4.1.4 Analysis of the Nuclear Fraction
lOOfil aliquots of each nuclear suspension was added to 5ml aliquots of 0.9% 
buffered NaCl immediately prior to pouring on a prewetted whatman Gf7c filter disc 
(2.5cm) held in a millipore filter apparatus. The test-tube and chimney of the apparatus 
were washed with 3x4ml aliquots of saline. The filters were transferred to scintillation 
vials to which 4mls of Ecosint A was added. The vials were counted for tritium each 
for lmin and the cpm used to carry out computerised scatchard calculations.
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4.1.5 Steroid Standards
Ten radioactive steroid standards were prepared, seven radiolabelled standards 
within the stated range (0.2-3.OnM of [3H] oestradiol-17(3 (ER assay) and 0.5-5.0 nM 
of [3H]-Org 2058 (PR assay)) (standards 1-7) plus an additional three duplicate 
standards of the highest three concentrations with a 100-fold excess of non-labelled 
competitor (standards, 8,9 &10). First unlabelled steroid was added to tubes 8, 9 and 
10 and then the solvent was evaporated using compressed air. To each vial, 
appropriate volumes of tritiated steroid, ethanol and HED buffer were added to a 
volume of 1ml. Aliquots of 50pl of each standard were counted to obtain a value of 
the "totals". The cpm were used to carry out computerised Scatchard calculations. 
Scatchard analysis (Scatchard, 1949) of ligand binding assay data was routinely 
carried out using a BBC microcomputer program as described by Leake et al., (1987). 
The program calculates the mean non-specific binding correction factor from assay 
samples 8-10. This mean value is then used to calculate the component of the counts 
in samples 1-7 which represents specific binding. A saturation curve is plotted and 
then analysed by the methods of Scatchard.
The concentrations and ligands used for each receptor assay standard were as 
follows.
o For ER assay: 0.2, 0.3, 0.5, 0.75, 1.5, 2.0, & 3.0 nM final concentration [3H]- 
oestradiol-17P was used as the radiolabel with a 100-fold excess of diethylstilboestrol 
(DES) as the competitor in the highest three concentrations. The [3H]-oestradiol- 17P 
had a specific activity of 55.4 Ci/mmol. (HE buffer replaces HED buffer in the ER 
assay).
o For PR assay: 0.5, 0.75, 1.0, 2.0, 3.0, 4.0, & 5.0 nM final concentration [3H|- 
Org 2058 was used as the radiolabel with a 100-fold excess of cold Org 2058 as the 
competitor in the highest three concentrations. The [3H]-Org 2058 had a specific 
activity of 52 Ci/mmol.
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4.1.6 Progesterone "Two-point competition" Steroid Receptor Assay
The ten point LBA of cell culture extracts were initially used to assay the 
progesterone receptor content of cells exposed to drug, and hormone supplements 
grown in 175cm2 flasks. However, these experiments were very difficult to perform 
because the cells would not always continue to grow once the supplement had been 
added. Attempts were made to alter the initial seedings numbers of cells before adding 
the supplements in the hope that a large enough number of cells could be maintained 
for the duration of the experiments. This, however, proved fruitless. Over a peroid of 
four months the experiments were only completed with a limited number of flasks.
Due to this lack of success, the abbreviated two-point assay was used. This relies 
upon straightforward competition between tritated ligand and excess unlabelled 
competitor (Leake and Habib 1987). The experiments were carried out in triplicate, 
per experiment, in 6 well tissue culture plates. The assay involves incubating the cells 
with 2mls of medium containing either tritiated Org 2058 (1X10'^M) (1) or tritiated 
Org 2058 (1x10"9m ) plus excess cold Org 2058 (1X10“^ M) (2) for 30mins at 37°C. 
The cells were washed 3 times with PBS-A to remove all tritiated media and the cells 
were incubate for 15mins at 4°C after the addition of 1ml of absolute alcohol. The 
alcohol was transferred to scintillation vials to which 4mls of Ecosint A was added. 
The vials were counted for tritium, each for lmin and the concentration of bound 
steroid was determined by subtracting (2) from (1). The counts per minute were then 
converted to the number of moles of bound steroid per litre. This was achieved by 
converting the cpm into cpm per litre and then into the disintegrations per minute.
This gave the number of pCi and by knowing the number of Ci per mole of stock it 
was possible to calculate number of mole of bound steroid per litre. So that samples 
could be compared, the total number of moles of bound steroid was converted into the 
number of femtamoles per |ig of DNA. Because of problems with DNA recovery of 
cells harvested (alcohol extracted) for receptor content, DNA content was determined
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for cells in parallel wells. DNA content was determined using the Hoechst assay as 
descibed in Methodology section 3.1..
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EXPERIMENTAL
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1 Oestrogen and Progesterone Receptor Analysis of ZR-75 and MCF-7 Cells
1.1 INTRODUCTION
The long-term objective of this study was to assess the in vitro regulation of the 
progesterone receptor. In particular, it was of interest to establish whether the 
minimum gynaecologically-effective dose of Norethisterone (approx. 10"^M) had any 
influence on the effect of Tamoxifen plus/minus Megace on the synthesis of the 
progesterone receptor. Initially it was necessary to quantitate the normal content of 
oestrogen and progesterone receptor in the human breast cell lines ZR-75 and MCF-7 
grown under normal cell culture conditions in routine RPMI medium Quality control 
samples were also assayed for PR and ER content to establish the accuracy and 
reproducibility of the assay.
1.2 METHOD
ZR-75 and MCF-7 cells were cultured routinely in 175cm^ plastic tissue culture 
flasks as described in METHODOLOGY section 2.2. When the cells reached about an 
80% confluent cell monolayer, cells were washed with PBS-A and 2mls of the 
appropriate buffer for either the oestrogen or progesterone receptor assay was added. 
The cells were harvested with a rubber policeman and transferred into sterile 
universals. The cell suspension was then analysed for either oestrogen or progesterone 
receptor content as described in METHODOLOGY section 4.1.2. Aliquots (1 OOjul) of 
either cytosol or nuclear fractions were assayed for protein using the Bradford Protein 
assay or DNA using the Hoeschst DNA assay described in METHODOLOGY section
3.2 and 3.1 respectively. Lyophilised quality control samples were resuspended in a 
10% glycerol deionised H2O solution. These samples were then treated as cytostolic 
fractions for steroid receptor analysis. 100 pi aliquots of the suspension were assayed 
for protein content.
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1.3 RESULTS
The results described in TABLE 1 are for quality control material provided by the 
EORTC Receptor Group and represent the means of 3 separate experiments, each 
experiment consisting of triplicate ER or PR assay so that the values represent the 
mean of 9 assays. The mean results published by the EORTC Receptor study group 
are also shown. The results in TABLE 1 also describes the total content of PR and ER 
found in ZR-75 and MCF-7 cells. The result as shown in FIGURES 8 and 9 represent 
the mean of four experiments for each cell line, each experiment consisting of cells 
from one 175cm^ plastic tissue flask. Receptor content is expressed as: cytosolic 
fraction, femtomoles per mg of protein and nuclear fraction, femtomoles per pg of 
DNA in FIGURE 8. In FIGURE 9 the nuclear and cytosol values are expressed as 
femtomoles per pg of DNA, allowing comparisons to be made between the relative 
distribution of ER and PR in the cell lines.
TABLE 1
Oestrogen And Progesterone Receptor Analysis of Quality Control Sample 1991-A
Steroid
Receptor
Assay
ER
PR
Receptor
Content
(fmol/mg
protein)
4.94
86.63
Std Devn Kd Std Devn No. Of Expts
(xio-10M)
2.35
6.61
5.35
7.74
2.14
1.03
EORTC RECEPTOR STUDY GROUP QUALITY CONTROL
FIGURES 
Mean St. Devn.
ER 18.60 8.40
PR 106.70 54.70
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The Total Concentration of ER and PR Determined by the Ligand Binding Assay in
Steroid
Receptor
Assay
MCF-7 Cells 
ER 
PR 
ZR-75 Cells 
ER 
PR
Receptor 
Content 
(finol/ug of 
DNA)
2.41
13.56
6.83
9.92
MCF-7 and ZR-75 Cells
St. Devn No. Of Expts
0.63
1.64
1.50
1.96
66
Fig.8 Oestrogen and progesterone receptor analysis of ZR-75 and MCF-7 cells grown 
in routine medium. Both cell lines were grown in separate 175cm2 plastic tissue culture 
flasks in routine RPMI medium until the cells reached about an 80% confluent cell 
monolayer formed. The cells were harvested and the ER and PR content was 
measured as described in METHODOLOGY section 4.1.2.
Error bars represent the Standard Deviation of the Data.
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Fig. 9 Oestrogen and progesterone receptor analysis of ZR-75 and MCF-7 cells 
grown in routine medium. Both cell lines were grown in separate 175cm2 plastic tissue 
culture flasks in routine RPMI medium until the cells reached about an 80% confluent 
cell monolayer formed. The cells were harvested and the ER and PR content was 
measured as described in METHODOLOGY section 4.1.2. The nuclear and cytosol 
values are expressed as femtomoles per pg of DNA.
Error bars represent the Standard Deviation of the Data.
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Fig. 10 Representative Scatchard Analysis of Ligand Binding Assay Data. The total 
concentration of receptor was determined from the total number of radioactive counts 
per minute in each fraction by Scatchard analysis (Scatchard, 1949). The Scatchard 
calculations were carried out using a BBC microcomputer program. A minimum of 
four points were selected to generate each plot (Leake et al., 1987).
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Scatchard  Analysis Of Ligand Binding Data
A Representative Scatchard Plot of the Oestrgoen Ligand Binding Assay Of MCF-7 Cells
<0eU-,
•3c
3O
PQ
1.5000E-01
1.0000E-01 -
5.0000E-02 -
i-H
p6
>o vo r-
Bound
00 OV
Kd = 3.850xl0-10M
A Representative Scatchard Plot of the Progesterone Ligand Binding Assay Of ZR-75 Cells
82uu
■3e3oBQ
2.0000E-01
1.5000E-01 -
1.0000E-01 -
5.0000E-02 -
o o
I
tLj
00 OV
Bound
Kd = 3.366x10-10M
A Representative Scatchard Plot of the Oestrogen Ligand Binding Assay of EORTC Samples
U h
•3c
3O
CQ
6.0000E-02
5.0000E-02 -
4.0000E-02 -
3.0000E-02 -
2.0000E-02 -
1.0000E-02
( N
ri
Kd = 5.048xl0-10M
Bound
i.4 C o n c l u s io n
There is a large difference in the concentration of ER published by the EORTC 
Receptor Study Group and those found in this study. This difference is probably due 
to the age of the Quality Control sample used. Over duration between storage 
(approx. 2 years) and use, it is likely that some of the ER in the sample has degraded. 
The concentration of PR cited in this study for the qualtiy control sample is well 
within the range quoted by EORTC. Therefore, this demonstrates that the ligand 
binding assay for either ER or PR is reproducible, though absolute accuracy of ER 
was not confirmed.
As can be seen from FIGURE 8 both cell lines are oestrogen and progesterone 
receptor positive. MCF-7 and ZR-75 cells (TABLE 1 and FIGURE 9) in their total 
concentration of ER and PR but demonstrated equivalent distribution of each 
receptor. The MCF-7 cells produce a higher concentration of that PR than ZR-75 cells 
which contains higher levels of ER The distribution of PR is favoured towards the 
nuclear region of each cell line while the ER receptor demonstrates an ability to be 
evenly distributed thought the cells.
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2 Progesterone Receptor Induction By Tamoxifen In
ZR-75 Cells
2.1 INTRODUCTION
Having established that PR content could be reliably measured it was necessary to 
determine the effects of Tamoxifen on the induction of PR in ZR-75 cells during 96 
hours of exposure. The concentration of Tamoxifen used throughout this study was 
that which previous experiments in our laboratory had been shown to be effective in 
breast cancer cells in vitro.
2.2 METHOD
ZR-75 cells were cultured routinely in 175cm^ plastic tissue culture flasks until the 
cell monolayer was between 80-90% confluent. The cells were harvested using 
trypsin/versene solution and reseeded into ten 6-well plastic tissue culture plates at a 
cell density of 7.5 to 8.5x10^ cells per well. The cells were allowed to "plate down" 
for 24 hours. The cells were washed with PBS-A and five 6-well plastic tissue plates 
were fed with phenol red free medium with 5% HIDCCFS plus Tamoxifen (lxlO“^ M) 
or ethanol at a volume equivalent to the supplement (as the control). Every 24 hours 
starting from time zero for 96hours, one 6 well plastic tissue plate was selected from 
each medium to determine the PR content using the progesterone two point 
competition steroid assay as described in METHODOLGY section 4.1. Four wells 
were used for the progesterone receptor analysis and from the other two wells the 
cells were harvested using trypsin/versene solution and the cell suspension was 
transferred to eppendorf. 200fil of ETN buffer containing 0.1% SDS was added to 
each eppendorf and incubated for 30 mins at 37°C. Aliquots (100fil) of solubilised 
cells were assayed for DNA using the Hoeschst DNA assay as described in 
METHODOLGY section 3.1.
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2.3 RESULTS
FIGURE 11 shows the time course of Tamoxifen regulation of PR synthesis. Each 
data point is the mean of 3 separate determinations. The parameter being measured is 
progesterone receptor content and so the results are expressed as femtomoles per fig 
of DNA.
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Fig.ll Time course of Tamoxifen induction of PR in ZR-75 cells. ZR-75 cells grown 
in 175cm2 plates were reseeded into 6 well plates at a density of 7.5 to 8.5x10^ 
cells/well before the addition of Tamoxifen (lxlO'^M) or vehicle. The cells were then 
incubated for up to 96hrs at 37°C and the media was changed after 2 days. Wells 
were selected every 24hours to measure PR content using a two point receptor assay 
as described in METHODOLOGY section 4.1. Each data point represents PR content 
expressed as femtomoles per (ixg of DNA.
Error bars represent the standard Deviation of the Data.
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Progesterone Receptor Induction in ZR-75 cells
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FIGURE 11 demonstrates the effects of Tamoxifen and the control on the induction 
of PR in ZR-75 cells. What is interesting is that the PR levels should fall so 
dramatically after the initial introduction of the new medium Possibly this could be 
due to a trauma response induced by the changes from one type of media to another. 
After 48 hours exposure to the new media, Tamoxifen treated cells start to show 
induction of the PR Future experiments would therefore need to have a duration 
longer than 48 hours, allowing the effects of the supplements on PR synthesis to be 
observed. Interestingly this phenomenon can also be observed in those cells treated as 
the control after 72 hours. The control media contained no supplement that should 
have been able to induce PR Therefore, the most likely explanation is that the cells 
were starting to become over confluent. However, initial work demonstrated that the 
cells tended to become over confluent some time between 96 hours and 120 hours in 6 
well plates when seeded at the cell density described in this method section. When the 
cells reached a confluent state it had been observed that they synthesised higher levels 
of PR than when they are growing normally (observations of R  E. Leake and co­
workers). This would imply that the duration of further experiments studying the role 
of the PR needs to start 24 hours after the seeding of the wells, and needs to be longer 
than 48 hours after the initial introduction of the supplement, but no longer than 96 
hours when cells become over confluent.
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3 The Effects of Drug And Hormone Treatments on Progesterone Receptor
Content In ZR-75 cells.
3.1 INTRODUCTION
Studies were developed to determine the influence of oestrogens and antiestrogens 
on PR content. On the basis of experiment 2.3 the experiments were designed so that 
the cells were exposed to a supplement for 96hours at 37°C. The cells progesterone 
receptor content was measured by using the progesterone two point competition 
steroid receptor assay.
3.2 METHOD
ZR-75 cells were cultured routinely in 175cm^ plastic tissue culture flasks until the 
cell monolayer was between 80-90% confluent. The cells were harvested using 
trypsin/versene solution and reseeded into 6-well plastic tissue culture plates at a cell 
density of 7.5 to 8.5 xlO^ cells per well. The cells were allowed to plate down for 
24hours. The cells were washed with PBS-A and each plastic tissue plate was fed with 
phenol red free medium with 5% HIDCCFS plus ethanol to an equal volume as the 
supplements (as the control) or a hormone supplement; Oestradiol ( l x l O ' a n d  
3x10"9m ), Tamoxifen (lxlO'^M) or ICI 182,780 (lxlO"^M) was added. After 
48hours each set of plates was washed with PBS-A and fed. After 96 hours the cells 
were washed with PBS-A and then assayed for PR using the progesterone two point 
competition steroid receptor assay described in METHODOLOGY section 4.1.
The concentrations of Oestradiol used throughout this study are equivalent to the 
range of Oestradiol found in the plasma of pre-menopausal women. The antiestrogen 
ICI 182,780 has not been administered to patients, but the level chosen for this 
supplement is equivalent to that for Oestradiol because the affinity of ICI 182,780 for 
ER is similar to that of E2.
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3.3 RESULTS
The results shown in FIGURE 12 represent the mean of 3 experiments, each 
experiment consisting of 3 samples for each medium used. The parameter being 
measured is the progesterone receptor content, so the results are expressed as the 
concentration of bound receptor as a percentage of the control. The results described 
in TABLE 2 represent the above data illustrated as the progesterone receptor content 
expressed as fmol/pg DNA of the original cell pellet. Because of problems with DNA 
recovery of cells harvested (alcohol extracted) for receptor content, DNA content was 
determined for cells grown in parallel wells. (See EXPERIMENTAL section 13.3 - 
TABLE 6). Variation in DNA content amongst wells (for identical growth conditions) 
had been previously demonstrated to be less than 10%.
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TABLE 2
Progesterone Receptor Analysis Of ZR-75 Cells Exposed to Hormone and Drug
Supplements.
Hormone or Drug Receptor Content ST Devn No. Of Expts
Supplement (fmol/mg of DNA1
Control 0.479 0.036 3
Oestradiol (1x10" 0.688 0.342 3
9M)
Oestradiol (3x10" 0.641 0.368 3
9M)
Tamoxifen (1x10- 0.568 0.079 3
9M)
ICI 182,780(1x10- 0.423 0.046 3
9M)
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Fig.12 Effects of Oestradiol, Tamoxifen and ICI 182,780 on progesterone receptor 
concentration in ZR-75 cells. ZR-75 cells grown in 150 cm^ plates were reseeded into 
6 well plates at a density of 7.5 to 8.5X10^ cells/well before the addition of 
compounds. Oestradiol (1X10"^M and 3X10“^ M), Tamoxifen (1X10"^M), ICI 182,780 
(1x10“9m ), or vehicle were incubated for up to 96hrs at 37°C. Media was changed 
after 2 days. Progesterone receptor concentration was measured using a two point 
progesterone receptor assay as described in METHODOLGY section 4.1.
The't' test was used to measure the difference between the PR content of cells 
exposed to a supplement and the control cells and values are given below for each 
condition.
(i>p < 0.2, comparing Oestradiol (lxlO“^ M) to the control.
(2) P < 0.1, comparing Oestradiol (3xl0“^ M) to the control.
(3) P < 0.1, comparing Tamoxifen (lxlO'^M) to the control.
(4) P < 0.05, comparing ICI 182,780 (lxlO'^M) to the control.
Error bars represent the Standard Deviation of the Data.
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Summary of the Effects of Drug and Hormone Treatments on
Progesterone Receptor Content in ZR-75 cells
1 1
Hormone Treatment
E3 CONTROL
□ OESTRADIOL 1-M0-9M
□ OESTRADIOL 3X10-9M
TAMOXIFEN 1M0-9M
m ICI 182,780 1M 0-9M
3.4 C o n c lu s io n
Initial observations of FIGURE 12 reveal that the PR concentration in 1 and 3x10" 
(P<0.2 and P<0.1, respectively) Oestradiol and Tamoxifen (P<0.1) treated cells 
are higher than the control value ( the ‘P’ values are not significant due to the small 
number of samples). This profile is due to the ability of oestrogens to stimulate the 
synthesis of the progesterone receptor. As previously stressed, activated ER has the 
ability to bind to ERE's 5' to and 3' to the PR gene, inducing synthesis. Tamoxifen 
demonstrates partial oestrogenic qualities with its ability to induce synthesis of PR.
It was interesting to note that the PR levels in ZR-75 cells after exposure to ICI 
182,780 were significantly (P<0.05) lower than those in the control level. This implies 
that something in the control growth medium remains oestrogenic (RIA showed no 
detectable E2 in stripped medium) or that the pre-experimental washing does not fully 
remove oestrogens.
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4 The Effect Of Progestins On Progesterone Receptor Content In ZR-75 Cells
4.1 INTRODUCTION
Progestins, such as Megace, are known to be effective in treating hormone-sensitive 
breast cancer. Their action is assumed to be mediated through the PR. It was of 
interest to compare the effects of Norethisterone at the range used to reduce vaginal 
bleeding (~10"^M), with a dose of Megace (1x10'7M), a progestin used in the study 
by Leake et al (1993).
4.2 METHOD
The experiment was performed as described in EXPERIMENTAL section 3.2. 
except the following supplements were used instead of those described in 
EXPERIMENTAL section 3.2; Norethisterone (1, 3 and 5xlO"^M) or Megace (1x10" 
7M).
4.3 RESULTS
The results shown in FIGURE 13 represent the mean of 3 experiments, each 
experiment consisting of 3 samples for each medium used. The parameter being 
measured is progesterone receptor content, so the results are expressed as the 
concentration of bound receptor as a percentage of the control. The results described 
in TABLE 3 represent the above data illustrated as the amount of PR in femtomoles 
per jig of DNA. Consistent DNA samples could not be obtained from the 
experimental (alcohol-treated) wells and so the results in TABLE 3 were calculated 
from the DNA content of samples in identical growth conditions measured by the 
Hoescht assay. (See EXPERIMENTAL section 13.3 - TABLE 6).
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TABLE 3
Progesterone Receptor Analysis Of ZR-75 Cells Exposed to Progestin Supplements
Progestin Receptor Content ST Devn No. Of Expts
Supplement (finol/mg of DNA1
Control 0.786 0.317 3
Norethisterone 0.969 0.399 3
(Ixl0-9M)
Norethisterone 0.668 0.585 3
(3xlO-9M)
Norethisterone 0.536 0.428 3
(5xl0-9M)
Megace ( lx10- 0.552 0.391 3
7M)
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Fig. 13 Effects of Norethisterone and Megace on progesterone receptor concentration 
in ZR-75 cells. ZR-75 cells grown in 150cm^ plates were reseeded into 6 well plates 
at a density of 7.5 to 8.5x10^ cells per well before the addition of compounds. 
Norethisterone (1, 3, and 5xlO"^M), Megace (lxlO"^M) or vehicle were incubated 
for up to 96hrs at 37°C. Media containing compounds were changed after 2 days. 
Progesterone receptor concentration was measured using the progesterone "two- 
point competition" steroid receptor assay as described in METHODOLOGY section 
4.1.
The't' test was used to measure the difference between the PR content of cells 
exposed to a supplement and the control cells and values are given below for each 
condition.
(1) P < 0.2, comparing Norethisterone ( lxlO"*M) to the control.
(2) P < 0.5, comparing Norethisterone (5x10""m) to the control
(3)P<0.1 , comparing Megace (lxlO'^M) to the control.
Error bars represent the Standard Deviation of the Data.
82
Summary of the Effects of Progestins on Progesterone 
Receptor content in ZR-75 cells.
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4.4 Co n c l u s io n
FIGURE 13 demonstrates the role of progestins in the regulation of the 
progesterone receptor content. Treatment with a low dose progestin,
N orethisterone( 1x10" ^ M) induces (p<0.2) a higher concentration of PR in comparison 
to the control. Alternatively the highest dose of Norethisterone and Megace have 
(p<0.5 and p<0.1 respectively) lower values than the control. Norethisterone appears 
to span the contrasting results. ( The ‘P’ values may not be significant due to the small 
sample size).
In conclusion, it appears that the actions of progestins on the PR is dependant upon 
the dosage of the treatment. Low dose treatments of progestins maintain higher levels 
of PR either by inducing the synthesis of PR or by slowing down the degradation of 
the protein. Higher doses of treatments reduce the level of PR in the cells.
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5 The Effects Of Tamoxifen plus Progestin On Progesterone Receptor Content
In ZR-75 Cells
5.1 INTRODUCTION
It has been established that Tamoxifen due to its partial oestrogen properties can 
maintain high levels of PR over a 96 hour period. In view of these results it was 
decided to determine the effect of progestins on Tamoxifen induction of PR after 96 
hours.
5.2 METHOD
The experiment was performed as described in EXPERIMENTAL section 3.2. 
except the following supplements were used instead of those described in 
EXPERIMENTAL section 3.2; Tamoxifen (lxlO'^M) or Tamoxifen plus 
Norethisterone (1, 3 and 5xlO"^M) or Megace (lxlO“^ M and lxlO^M).
5.3 RESULTS
The results shown in FIGURE 14 represent the mean of 3 experiments, each 
experiment consisting of 3 samples for each medium used. The parameter being 
measured is progesterone receptor content, so the results are expressed as the 
concentration of bound receptor as a percentage of the control. The results described 
in TABLE 4 represent the above data illustrated as the amount of PR in femtomoles 
per jig of DNA using DNA content of competition wells as described in 
EXPERIMENTAL section 13.3 - TABLE 6.
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TABLE 4
Progesterone Receptor Analysis Of ZR-75 Cells Exposed to Tamoxifen Plus Progestin
Supplements
Tamoxifen + Receptor Content ST Devn No. Of Expts
Progestin ffrnol/mg of DNA1
Supplement
Control 0.476 0.034 3
Tamoxifen (1x10" 0.519 0.051 3
9M)
Tamoxifen + 0.569 0.038 3
Norethisterone 
(1x10-9M)
Tamoxifen + 0.231 0.020 3
Norethisterone 
(3x10"9M)
Tamoxifen + 0.334 0.179 3
Norethisterone 
(5x10”9M)
Tamoxifen + 0.252 0.043 3
Megace ( lx10"7)
Tamoxifen + 0.357 0.126 3
Megace ( lx10"8)
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Fig.14 Effects of Tamoxifen plus Norethisterone or Megace at varying molarities on 
progesterone receptor concentration in ZR-75 cells. ZR-75 cells grown in 150cm^ 
plates were reseeded into 6 well plates at a density of 7.5 to 8.5x10^ cells/well before 
the addition of compounds. Tamoxifen (lxlO'^M ), Tamoxifen plus Norethisterone (1, 
3, and 5xl0"^M), Megace (1x10"^M and lxlO'^M) or vehicle were incubated for up 
to 96hrs at 37°C. Media containing compounds were changed after 2 days. 
Progesterone receptor concentrations were measured using a two point receptor assay 
as described in METHODOLOGY section 4.1.
The't' test was used to measure the difference between the PR content of cells 
exposed to a supplement and control cells and values are given below for each 
condition.
(1) P<0.1 , comparing Tamoxifen ( 1\10“^M) to the control.
(2) P < 0.05, comparing Tamoxifen plus Norethisterone (lxlO'^M) to the control.
(3)P < 0.01, comparing Tamoxifen plus Norethisterone (3\10"^M) to the control.
(4) P < 0.1, comparing Tamoxifen plus Norethisterone (5xl0"®M) to the control
(5)P < 0.05, comparing Tamoxifen plus Megace (1x10“^ M) to the control.
Error bars represent the Standard Deviation of the Data.
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Summary of the Effects of Tamoxifen plus Progestin on 
Progesterone Receptor Content in ZR-75 cells.
150
100
50
0
Hormone Treatment
£ 3  CONTROL 
□  TAMOXIFEN U10-9M
0  TAMOXIFEN 1M0-9M + NORETHISTERONE U10-9M  
0  TAMOXIFEN 1*10-9M + NORETHISTERONE 3M0-9M  
£ 3  TAMOXIFEN 1X10-9M + NORETHISTERONE 5X10-9M 
0  TAMOXIFEN 1X10-9M + MEGACE U10-7M  
&  TAMOXIFEN 1X10-9M + MEGACE 1*10-8M
5.4 CONCLUSION
FIGURE 14 demonstrates that progestins can overcome the oestrogenic effects of 
Tamoxifen on P R . It has been demonstrated in the cell line T47D that the half-life of 
the PR is reduced in the presence of progestins (Nardulli et al., 1988).
However, what is interesting is that the progestin, Norethisterone at a concentration 
of lxlO'^M  with (P<0.05) or without (P<0.2) Tamoxifen should induce higher 
concentrations of PR in comparison to the control. Upon comparing these treatments 
with Tamoxifen alone it can be observed that there is no significant difference between 
any of the treatments. Therefore in terms of the long term aim of this study 
Norethisterone (lxlO '^M ) dose not affect the ability of Tamoxifen to induce the 
synthesis of PR However, the results also propose that progestins can also regulate 
the level of PR within hormonally sensitive cells as well as oestrogenic compounds.
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6 The Effects Of ICI 182,780 plus Progestin On Progesterone Receptor
Content In ZR-75 Cells.
6.1 INTRODUCTION
It has been established that the pure antiestrogen, ICI 182,780 does not induce any 
synthesis of the PR. On the basis of experiments 3.3, 4.3 and 5.3, Norethisterone 
(lxlO'^M), in the presence or absence of Tamoxifen, demonstrates no significant 
difference to that induced by Oestrodial in vitro. In view of these results it was 
decided to determine whether low dose progestin could maintain high levels of PR in 
the presence of ICI 182,780.
6.2 METHOD
This experiment was performed as described in EXPERIMENTAL section 3.2, 
except the following supplements were used instead of those described in 
EXPERIMENT AL section 3.2; Tamoxifen (lxlO'^M) or Tamoxifen plus 
Norethisterone (1, 3 and 5xl0"^M) or Megace (lxlO"^M and lxlO“^ M).
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6.3 RESULTS
The results shown in FIGURE 15 represent the mean of 3 experiments, each 
experiment consisting of 3 samples for each medium used. The parameter being 
measured is progesterone receptor content, so the results are expressed as the 
concentration of bound receptor as a percentage of the control. The results described 
in TABLE 5 represent the above data illustrated as the amount of PR in femtomoles 
per (j,g of DNA. Consistent DNA samples could not be obtained from the 
experimental (alcohol-treated) wells so the results in TABLE 5 were calculated from 
the DNA content of samples in identical growth conditions measured by the Hoescht 
assay. (See EXPERIMENTAL section 13.3 - TABLE 6).
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TABLE 5
ICI 182.780 +
Progestin 
Control 
ICI 182,780(1x10"
9M)
ICI 182,780 +
Norethisterone 
(1x10"9M)
ICI 182,780+ 0.441
Megace (1x10"^
M)
ICI 182,780 + 0.379
Megace (1x10"^
M)
St Devn No. Of Expts
0.346 3
0.046 3
0.068 3
0.134 3
0.088 3
Progesterone Receptor Analysis Of ZR-75 Cells Exposed To ICI 182.780 Plus
Progestin Supplements.
Receptor Content 
(frnol/mg of DNA)
0.528 
0.423
0.358
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Fig. 15 Effects of ICI 182,780 plus Norethisterone or Megace on progesterone 
receptor concentration in ZR-75 cells. ZR-75 cells grown in 150cm^ plates were 
reseeded into 6 well plates at a density o f40,000 cells/well before the addition of 
compounds. ICI 182,780 (1x10"^), ICI 182,780 plus Norethisterone (1,3 and 5x10" 
^M) or Megace (lxl0"^M and lxl0"^M) were incubated for 
up to 96hrs at 37°C. Media containing compounds were changed after 2 days. 
Progesterone receptor concentration was measured using a two point progesterone 
receptor assay as described in METHODOLOGY section 4.1.
The't' test was used to measure the difference between the PR content of cells 
exposed to a supplement and control cells and values are given below for each 
condition.
(1) P < 0.05, comparing ICI 182,780 (lxlO'^M) to the control
(2) P < 0.2, comparing ICI 182,780 plus Norethisterone (lxl0"^M) to the 
control
(3) P < 0.1, comparing ICI 182,780 plus Megace (lxl0"^M) to the control.
Error bars represent the Standard Deviation of the Data.
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Summary of the Effects of ICI 182,780 plus Progestins 
on Progesterone Receptor Content in ZR-75 cells.
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6.4 CONCLUSIONS
The low amount of progesterone receptor present in cells exposed to ICI 182,780 
on its own or with a progestin in FIGURE 15 demonstrates the dependence of the PR 
on ER for synthesis. What is interesting is that the level of PR present in cells exposed 
to both antiestrogen and progestin should approximately range between 80%-90% of 
the control value. It has been demonstrated in previous experiments that progesterone 
on their own or in the presence of Tamoxifen have the ability to reduce PR levels to 
approximately 50% of that of the control. Data from the human breast cell line T47D 
demonstrates that the half-life of the progesterone receptor is reduced from 21 hours 
for unoccupied PR to 6 hours when progestins are present (Nardulli et al., 1988). 
Therefore, if ICI 182,780 is preventing the synthesis of PR by ER and the progestins 
have increased the rate of PR degradation, the level of detectable PR in comparison to 
the control should be very low. It has also been established that a low dose of 
Norethisterone does not alter the level of PR in the absence of oestrogens. These 
results would suggest that ICI 182,780 has the ability to overcome some of the 
biological actions of progestins.
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7 The Effect of Hormonal Treatments On the Growth of ZR-75 And MCF-7
Cells
7.1 INTRODUCTION
The synthesis of the progesterone receptor is regulated by an oestrogen 
hormone response elements 5' and 3' to the gene. In the presence of oestradiol the 
oestrogen receptor binds to the ERE stimulating the synthesis of the progesterone 
receptor. The oestrogen receptor also stimulates many other genes, some of which 
generate the mitogenic effects so readily seen in hormone sensitive cells. One of the 
objectives of this study was to investigate the way in which progestins modulate the 
agonist activity of Tamoxifen in inducing PR. As PR synthesis is partly cell cycle 
dependent it was necessary also to determine the effects of the various combinations 
of drugs on growth rates of MCF-7 and ZR-75 cells (Sutherland., 1993).
The cell line MCF-7 had proven difficult to work with while studying the levels of 
PR synthesis. However, this cell line in addition to ZR-75 cells proved to be an 
adequate model for studying the effects of hormonal supplements on cell proliferation.
7.2 METHOD
ZR-75 and MCF-7 cells were cultured routinely in 175cm^ plastic tissue culture 
flasks until the cell monolayer was between 80-90% confluent. The cells were 
harvested using trypsin/versene solution and reseeded into 24 well plates at a cell of 
1 . 7 - 2 . 5 x 1 0 " 4  cells per well. The cells were allowed to "plate down" for 24 hours. The 
cells were washed with PBS-A and each set of 10 wells were fed with phenol red-free 
medium with 5% HIDCCFCS plus alcohol at a volume equivalent to the supplements 
(as the control) or a hormone supplement; Oestradiol (lxlO’^M and 3xl0"^M), 
Tamoxifen (lxlO’^M) or ICI 182,780 (lxlO“^ M) was added. The cells were washed 
and fed with fresh medium every 48hours. Samples were removed every 24hrs for 
96hours from cells exposed to the various medium At each time point two wells were
93
selected, washed and harvested using trypsin/versene solution for each hormonal or 
drug supplement being studied. The cells were transferred to eppendorfs, spun down 
and stored at -20°C. When all samples had been removed 200pl of ETN buffer 
containing 0.1% SDS was added to each eppendorf and incubated for 30mins at 
37°C. Aliquots (lOOpl) of solubilised cells were assayed for DNA using the Hoechst 
DNA assay described in METHODOLOGY section3.1. To demonstrate that the 
concentration of DNA per sample was comparable with the number cells per ml, the 
two were plotted against each other (see figure 16). The cells were harvested from 
wells using trypsin/versene solution. The cells were transferred to eppendorfs, lOOpl 
of the sample was then used to determine the cell number per ml using a 
haemocytometer. The rest of the sample was assayed for DNA as before.
7.3 RESULTS
The results in FIGURE 16 demonstrates a correlation between cell number and DNA 
content.
The results shown in FIGURES 17 and 18 each represent the mean of 3 
experiments, each experiment consisting of 2 wells of cells for each time point. The 
parameter being measured is cell growth and so the results are expressed as the 
concentration of DNA (pg/ml) in relation to the duration of the experiment (hours).
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Fig 16. A correlation between DNA content and cell number. During several growth 
experiments samples were taken and both cell number (counted on the 
haemocytometer) and DNA content were measured (using the Hoescht DNA assay)
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Fig.17 Time course of the effects of Tamoxifen, Oestradiol and ICI 182,780 on the 
proliferation of ZR-75 cells over a 96hr period. ZR-75 cells grown in 175cm^ plates 
were reseeded into 24 well plates at a density of 17,500 to 22,500 cells/well before the 
addition of compound, Tamoxifen (lxlO'^M), Oestradiol (lx l 0"^M and 3xl0"^M), 
ICI 182,780 (1x10"^M) or vehicle. The cells were then incubated for 96hrs at 37°C. 
Media were changed after 2 days. Samples were removed every 24hrs and the DNA 
content was measured using the Hoechst assay as described in METHODOLOGY 
section 3.1. Each data point represents cell growth expressed as the concentration of 
DNA (pg/ml).
The't' test was used to measure the difference in cell proliferation between cells 
exposed to a supplement and the control cells at 96hrs and values are given below for 
each condition.
(1) P < 0.05, comparing Oestradiol (lxl0"^M) to the control.
(2) P < 0.05, comparing Oestradiol (3xl0“^ M) to the control.
Error bars represent the Standard Deviation of the Data.
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Summary of the Effects of Hormonal Treatments on the
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Fig.18 Effects of Tamoxifen, Oestradiol and ICI 182,780 on the growth of MCF-7 
cells over 96hrs. MCF-7 cells grown in 175cm^ plates were reseeded into 24 well 
plates at a density of 17,500 to 22,500 cells/well before the addition of compound, 
ethanol (as the control), Tamoxifen (lx l0 “^ M), Oestradiol (lxl0"^M and 3xl0"^M), 
ICI 182,780 (1x10“9m ) or vehicle. The cells were then incubated for 96hrs at 37°C. 
Media containing compounds were changed after 2 days. Samples were removed 
every 24hrs and the DNA content was measured using the Hoechst assay as described 
in METHODOLOGY section 3.1. Each data point represents cell growth expressed as 
the concentration of DNA (jig/ml).
Error bars represent the Standard Deviation of the Data.
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7.4 CONCLUSION
FIGURE 17 demonstrates the mitogenic effect of oestradiol on the cell line ZR-75. 
The significant proliferative effect of oestradiol lxlO'9 M and 3xl0'9 M (P<0.05 and 
P<0.05 repectively) during the time course experiment demonstrates that the 
oestrogen receptors measured in the initial experiment are functional and sensitive to 
hormonal treatment for ZR-75 cells. MCF-7 cells treated with oestradiol show no 
significant difference in growth rate when compared with the control (figure 18). This 
is also the case for the cells treated with Tamoxifen and ICI 182,780. The experiment 
in chapter 1 demonstrated that the MCF-7 cell-line is both ER and PR positive. 
Neither oestrogen or antiestrogen demonstrated an ability to induce the oestrogen 
receptor to influence the growth rate of the MCF-7 cells. This would suggest that the 
oestrogen receptors in the MCF-7 cell-line are not fully functional.
ICI 182,780 has been defined as a pure antiestrogen. The definition of a pure 
antiestrogen is a compound that prevents oestrogen from stimulating transcription.. 
ZR-75 cells incubated with ICI 182,780 showed no alteration in growth when 
compared with the control. Therefore, the ZR-75 cells can proliferate without the 
oestrogen receptor. Tamoxifen also demonstrated no significant difference in growth 
rate when compared with the control.
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8 Dose Dependent Growth of ZR-75 and MCF-7 Cells to Norethisterone.
8.1 INTRODUCTION
Having established the influence of oestrogens and antiestrogens on the growth of ZR- 
75 and MCF-7 breast cancer cell lines, it was decided to assess the action of the 
progestin, Norethisterone, on cell proliferation of the human breast cell lines, over a 
dose range of 1 x 1 0 " to 1x10"^M. This would provide data comparing the effects 
of high and low dose Norethisterone on breast cancer cells in vitro.
8.2 METHOD
Both cell lines were subcultured as described in EXPERIMENTAL section 7.2. 
After 24 hours the cells were washed with PBS-A and each set of 10 wells were fed 
with phenol red free medium with 5% HIDCCFCS plus ethanol (as the control) or a 
synthetic progestin supplement; Norethisterone was used at 1x10"^M, lxlO’^M and 
1x10"^M. Samples were removed as described in EXPERIMENTAL section 7.2.
8.3 RESULTS
The results shown in FIGURES 19 and 120 represent the mean of 3 experiments, 
each experiment consisting of 2 wells of cells for each time point. The parameter being 
measured is cell growth and so the results are expressed as the concentration of DNA 
(pg/ml) in relation to the duration of the experiment (hours).
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Fig. 19 Effects of Norethisterone on the growth of ZR-75 cells over 96hrs. ZR-75 
cells grown in 175cm^ plates were reseeded into 24 well plates at a density of 17,500 
to 22,500 cells/well before the addition of compound, Norethisterone (lxlO"^M, 
lxlO"^M and 1x10"^M) or vehicle. The cells were then incubated for up to 96hrs at 
37°C. Media containing compounds were changed after 2 days. Samples were 
removed every 24hrs and the DNA content was measured using the Hoechst assay as 
described in METHODOLOGY section 3.1. Each data point represents cell growth 
expressed as the percentage of DNA in relation to the control.
The't' test was used to measure the difference in cell proliferation between cells 
exposed to a supplement and the control cells at 96hrs and values are given below for j 
each condition. j
i
(1 )p  < 0.1, comparing Norethisterone (lxl0"°M) to the control. J
(2) P < 0.05, comparing Norethisterone (lxlO'^M) to the control. I
Error bars represent the Standard Deviation of the Data. I|
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Fig. 20 Effects of Norethisterone on the growth of MCF-7 cells over 96hrs. MCF-7 ;
cells grown in 175cm^ plates were reseeded into 24 well plates at a density of 17,500 j
|
to 22,500 cells/well before the addition of compound, ethanol (as the control), j
j
Norethisterone (lxl0"^M, lxl0"^M and 1x10" ^ M). The cells were then incubated for ] 
up to 96hrs at 37°C. Media was changed after 2 days. Samples were removed every 
24hrs and the DNA content was measured using the Hoechst assay as described in 
METHODOLOGY section 3.1. .Each data point represents cell growth expressed as I 
the percentage of DNA in relation to the control. j
Error bars represent the Standard Deviation of the Data.
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8.4 CONCLUSION
FIGURES 19 demonstrates the growth inhibition of the cell line ZR-75 mediated by 
the dose range of Norethisterone lx10'8 M and l x10'7 M (P<0.1 and P<0.05, 
respectively) over a period of 96 hours. As the concentration of progestin was 
increased so did the level of growth inhibition. What is interesting is that the progestin 
should have no effect on the ZR-75 cell line for at least the first 48 hours of exposure 
before growth inhibition is induced. Norethisterone (lxlO"^M) had no affect on the 
cell proliferation of ZR-75 when compared to the control.
The MCF-7 cells demonstrated no significant affects on cell proliferation when 
treated with Norethisterone (figure 20).
102
9 The Effect Of A Low Pose Range Of Progestins On The Growth Of ZR-75
And MCF-7 Cells
9.1 INTRODUCTION
It has been established that Norethisterone can inhibit cell proliferation of ZR-75 cells 
in the absence of oestrogens. The in vivo level of Norethisterone used 
to reduce vaginal bleeding is about 10“^ M. Given the differential effects of 1,3 and 
5x10-9M Norethisterone on PR, it was decided to see if these doses had differential 
effects on growth rates. Additionally, the plasma level of Megace, when used as an 
anti-cancer agent, is about 10“^  M. Therefore, it was also decided to compare the 
effects of an anti-cancer dose of Megace with in vivo levels of Norethisterone.
9.2 METHOD
Both cell lines were subcultured as described in EXPERIMENTAL section 2.2. 
After 24hours the cells were washed with PBS-A and each set of 10 wells were fed 
with phenol red free medium with 5% HIDCCFCS plus ethanol (as the control) or a 
synthetic progestin supplement; Norethisterone (1, 3 and 5x10“ ^ M) or Megace (1x10“ 
^M). Samples were removed as described in EXPERIMENTAL section 7.2.
9.3 RESULTS
The results shown in FIGURES 21 and 22 represent the mean of 3 experiments, 
each experiment consisting of 2 wells of cells for each time point. The parameter being 
measured is cell growth and so the results are expressed as concentration of DNA 
(tig/ml) in relation to the duration of the experiment (hours).
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Fig.21 Effects of progestins on the growth of ZR-75 cells over 96hrs. ZR-75 cells 
grown in 175cm^ plates were reseeded into 24 well plates at a density of 17,500 to
22,500 cells/well before the addition of compound, Norethisterone (13, and 5x10" j 
^M), Megace (1x10" ^ M) or vehicle. The cells were then incubated for 96hrs at 37°C. 
Media containing compounds were changed after 2 days. Samples were removed 
every 24hrs and the DNA content was measured using the Hoechst assay as described 
in METHODOLOGY section 3.1. .Each data point represents cell growth as the 
concentration of DNA (fig/ml) in relation to the duration of the experiment (hours).
Error bars represent the Standard Deviation of the Data.
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Fig.22 Effects of progestins on the growth of MCF-7 cells over 96hrs. MCF-7 cells 
grown in 175cm^ plates were reseeded into 24 well plates at a density of 17,500 to
22,500 cells/well before the addition of compound, ethanol (as the control), 
Norethisterone (13, and 5xl0“^ M), Megace (lxlO'^M) or vehicle. The cells were 
then incubated for 96hrs at 37°C. Media containing compounds were changed after 2 
days. Samples were removed every 24hrs and the DNA content was measured using 
the Hoeschst assay as described in METHODOLGY section 3.1. Each data point 
represents cell growth expressed as the concentration of DNA (fig/ml) in relation to 
the duration of the experiment (hours).
Error bars represent the Standard Deviation of the Data.
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9.4 CONCLUSION
FIGURE 21 and 22 demonstrates the effect of a low dose range of progestins on 
ZR-75 and MCF-7 cells. Over the time period studied (96 hours) Megace and 
Norethisterone had no significant affect on the cell proliferation of the ZR-75 and 
MCF-7 cells.
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10 The Effects Tamoxifen. With or Without Progestin, On Cell Growth.
10.1 INTRODUCTION
Having established that the lxlO"^M dose of Norethisterone did not significantly 
effect Tamoxifen induction of the progesterone receptor, it was deemed necessary to 
investigate the progestins role in the proliferation of the human breast cell lines in the 
presence or absence of Tamoxifen.
10.2 M e t h o d
Both cell lines were subcultured as described in EXPERIMENTAL section 2.2. 
After 24hours the cells were washed with PBS-A and each set of 10 wells were fed 
with phenol red free medium with 5% HIDCCFCS plus ethanol (as the control) or 
Tamoxifen or Tamoxifen plus a synthetic progestin supplement; Tamoxifen (1x10" 
^M) Tamoxifen plus Norethisterone (lxl0"^M) or Megace (lxl0"^M and lxl0"^M). 
Samples were removed as described in EXPERIMENTAL section 2.2.
10.3 RESULTS
The results shown in FIGURES 23 and 24 represent the mean of 3 experiments, 
each experiment consisting of 2 wells of cells for each time point. The parameter being 
measured is cell growth and so the results are expressed as the concentration of DNA 
(pg/ml) in relation to the duration of the experiment (hours).
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Fig.23 Effects of Tamoxifen plus Norethisterone or Megace on the growth of ZR- 
75 cells over 96hrs. ZR-75 cells grown in 175cm^ plates were reseeded into 24well 
plates at a density of 17,500 to 22,500 cells/well before the addition of compomd, 
Tamoxifen (lxlO"^M), Tamoxifen plus Norethisterone (lxlO'^M) Megace (lxlO"^M 
and lxlO"^M) or vehicle. The cells were then incubated for 96hrs at 37°C. Meiia 
containing confounds were changed after 2 days. Samples were removed even 24hrs 
and the DNA content was measured using the Hoechst assay as described in 
METHODOLOGY section 3.1. Each data point represents cell growth expressed as 
the concentration of DNA (|ig/ml) in relation to the duration of the experiment 
(hours).
Error bars represent the Standard Deviation of the Data.
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Fig.24 Effects of Tamoxifen plus Norethisterone or Megace on the growth of MCF- 
7 cells over 96hrs. MCF-7 cells grown in 175cm^ plates were reseeded into 21 well 
plates at a density of 17,500 to 22,500 cells/well before the addition of compound, 
ethanol (as the control) Tamoxifen (lxlO"^M), Tamoxifen plus Norethisteronj (1x10- 
9M), Megace (lxlO'^M and lxl0“^M) or vehicle. The cells were then incuba:ed for 
96hrs at 37°C. Media containing compounds were changed after 2 days. Samples 
were removed every 24hrs and the DNA content was measured using the Hoechst ] 
assay as described in METHODOLOGY section3.1. Each data point represent cell j 
growth expressed as the concentration of DNA (fig/ml) in relation to the duraion of \ 
the experiment (hours).
Error bars represent the Standard Deviation of the Data.
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10.4 CONCLUSION
The growth curves in FIGURES 23 and 24 demonstrate that Tamoxifen alone or in 
the presence of a progestin has no effect upon the ptoliferation of MCF-7 or ZR-75 
cells..
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11 The Effects Of Tamoxifen plus Norethisterone on the Growth of ZR-75 and
MCF-7 cells
11.1 INTRODUCTION
It has been established that when low dose Norethisterone (lxlO'^M) is used in 
combination with Tamoxifen on MCF-7 and ZR-75 cells, the cells do not experience 
growth inhibition. This is in contrast to the growth inhibitory effects mediated by 
Norethisterone (lxlO '^M  and 1x10'7M) on ZR-75 cells. Because of the differential 
effects of 1, 3 and 5x10'^M Norethisteorone on PR synthesis it was decided to 
investigate whether an increase in Norethisterone dosage in the presence of Tamoxifen 
could overcome the proliferative effects of the "antiestrogen".
11.2 METHOD
Both cell lines were subcultured as described in EXPERIMENTAL section 2.2.
After 24hours the cells were washed with PBS-A and each set of 10 wells were fed 
with phenol red free medium with 5% HIDCCFCS plus ethanol (as the control) or 
Tamoxifen or Tamoxifen plus Norethisterone; Tamoxifen (lxlO'^M) or Tamoxifen 
plus Norethisterone (1, 3 and 5xl0"^M) . Samples were removed as described in 
EXPERIMENTAL section 7.2.
11.3 RESULTS
The results shown in FIGURES 25 and 26 represent the mean of 3 experiments, 
each experiment consisting of 2 wells of cells for each time point. The parameter being 
measured is cell growth and so the results are expressed as the concentration of DNA 
(pg/ml) in relation to the duration of the experiment (horns).
I l l
Fig,25 Effects of Tamoxifen plus Norethisterone on the growth of ZR-75 cells over 
96hrs. ZR-75 cells grown in 175cm^ plates were reseeded into 24 well plates at a 
density of 17,500 to 22,500 cells/well before the addition of compound, Tamoxifen 
(lxlO"^M), Tamoxifen plus Norethisterone (1,3 and 5xl0"^M) or vehicle. The cells 
were then incubated for 96hrs at 37°C. Media containing compounds were changed 
after 2 days. Samples were removed every 24hrs and the DNA content was measured 
using the Hoechst assay as described in METHODOLOGY section 3.1. Each data 
point represents cell growth expressed as the concentration of DNA (fig/ml) in 
relation to the duration of the experiment (hours).
Error bars represent the Standard Deviation of the Data.
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Fig.26 Effects of Tamoxifen plus Norethisterone on the growth of MCF-7 cells over 
96hrs. MCF-7 cells grown in 175cm^ plates were reseeded into 24 well plates at a 
density of 17,500 to 22,500 cells/well before the addition of compound, ethanol (as 
the control), Tamoxifen (lxlO"^M), Tamoxifen plus Norethisterone (1,3 and 5x10" 
^M) or vehicle. The cells were then incubated for 96hrs at 37°C. Media containing 
compounds were changed after 2 days. Samples were removed every 24hrs and the 
DNA content was measured using the Hoechst assay as described in 
METHODOLOGY section3.1. Each data point represents cell growth expressed as 
the concentration of DNA (fig/ml) in relation to the duration of the experiment 
(hours).
Error bars represent the Standard Deviation of the Data.
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11.4 CONCLUSION
The data (figures 25 and 26) shows that exposure to Tamoxifen alone or in the 
presence of Norethisterone (1, 3 and 5xlO-9M) has no effect on the proliferative rate 
of MCF-7 and ZR-75 cell lines
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12 The Effect Of Inhibiting the Synthesis Of The Progesterone Receptor In The 
Presence Of A Progestin On Cell Growth
12.1 INTRODUCTION
Tamoxifen is a weak oestrogen agonist but the "pure" antiestrogen ICI 182,780 has 
no known agonist activity. ICI 182,780 exerts its biological activities by preventing 
the oestrogen receptor from acting as a transcription factor. Experiments were carried 
out to confirm that ICI 182,780 has no agonist growth activity in either cell line.
12.2 METHOD
Both cell lines were subcultured as described in EXPERIMENTAL section 2.2. 
After 24hours the cells were washed with PBS-A and each set of 10 wells were fed 
with phenol red free medium with 5% HIDCCFCS plus ethanol (as the control) or ICI
182,780 of ICI 182,780 plus Norethisterone; ICI 182,780 (1x10"9M) or ICI 182,780 
plus Norethisterone (1, 3 and 5xl0“9M ). Samples were removed as described in 
EXPERIMENTAL section 2.2.
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12.3 RESULTS
The results shown in FIGURES 27 and 28 represent the mean of 3 experiments, 
each experiment consisting of 2 wells of cells for each time point. The parameter being 
measured is cell growth and so the results are expressed as the concentration of DNA 
(pg/ml) in relation to the duration of the experiment (hours).
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Fig.27 Effects of ICI 182,780 plus Norethisterone or Megace on the growth of ZR- 
75 cells over 96hrs. ZR-75 cells grown in 175cm^ plates were reseeded into 24 well 
plates at a density of 17,500 to 22,500 cells/well before the addition of compound, ICI
182,780 (lxl0"^M), ICI 182,780 plus Norethisterone (lxl0"^M), Megace (1x10“ 
and lxl0“^M) or vehicle. The cells were then incubated for 96hrs at 37°C. Media 
containing compounds were changed after 2 days. Samples were removed every 24hrs 
and the DNA content was measured using the Hoechst assay as described in 
METHODOLOGY section 3.1. Each data point represents cell growth expressed as 
the concentration of DNA (|xg/ml) in relation to the duration of the experiment 
(hours).
Error bars represent the Standard Deviation of the Data.
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Fig.28 Effects of ICI 182,780 plus Norethisterone or Megace on the growth of 
MCF-7 cells over 96hrs. MCF-7 cells grown in 175cm^ plates were reseeded into 24 
well plates at a density of 17,500 to 22,500 cells/well before the addition of 
compound, ethanol (as the control), ICI 182,780 (lxlO'^M), ICI 182,780 plus 
Norethisterone (lxl0"^M), Megace (lxlO'^M and lxlO'^M) or vehicle. The cells 
were then incubated for 96hrs at 37°C. Media containing compounds were changed 
after 2 days. Samples were removed every 24hrs and the DNA content was measured 
using the Hoeschst assay as described in METHODOLOGY section 3.1. Each data 
point represents cell growth expressed as the concentration of DNA (p,g/ml) in 
relation to the duration of the experiment (hours).
Error bars represent the Standard Deviation of the Data.
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Discussion
In this study, ' two point' competition progesterone receptor assays and growth 
time course experiments were used to investigate the effects of a gynaecological doses 
of Norethisterone (10"^M) upon the in vitro regulation of the progesterone receptor. 
This dose of Norethisterone had no effect upon the proliferation of ZR-75 and MCF-7 
cell lines. Norethisterone (lxlO '^M ) did not alter the levels of PR in ZR-75 cells. 
Alternatively higher doses 5 x 10“ reduced the levels of PR The effect of 
Norethisterone on PR messenger RNA levels was not investigated.
The results of Tamoxifen on PR in ZR-75 cells demonstrate that the induction of 
PR by Norethisterone lxlO"^M is comparable with that of Tamoxifen alone or with 
Norethisterone. Therefore these results demonstrate that low dose Norethisterone has 
the ability to be oestrogenic in nature, stimulating the synthesis of PR However, 
higher concentrations of Norethisterone down regulate the synthesis of PR The 
purpose of this dual control has not been established. Work by Wei et al., (1988) 
suggests that the human PR autoregulates by binding to, and inhibiting transcription of 
the PR gene. If this proves correct then this explains why PR levels fall in the presence 
of Norethisterone (5xl0“^ M). However, this does not provide an explanation why 
Norethisterone (lxlO'^M) manages to induce PR synthesis. It is possible that the 
shortening of receptor half-life only occurs at higher concentrations of progestin and 
so the low concentration appears to have a relatively positive effect on PR levels. To 
demonstrate that bound PR interfered with the transcription of its gene, it would be 
interesting to perform foot-printing assays on this region of DNA, in the presence of a 
range of doses of Norethisterone. This would provide data demonstrating which 
proteins are bound 5’ to the PR gene during transcription and would define the role 
played by progestin bound PR If there exists a type of “seesaw” control of the PR 
gene by progestins, then the concentration of the progestin needed for the induction of 
PR synthesis bound by PR may differ amongst cell lines depending on the basal level
125
of PR Higher levels of basal PR may respond to lower levels of plasma progestin due 
to the ability of larger amounts of the unbound PR concentration to progestin within 
the cell.
Another possible explanation of the above results suggested by Jordan et al 
(1992) is that Norethisterone acts as a oestrogenic compound via the oestrogen 
receptor. This study used higher concentrations of progestin (10'7 M to 10'8 M), 
however, they demonstrated that the progestin Norethindrone could induce mitogenic 
effects. If this was a possible explanation for the induction of PR synthesis by 
Norethisterone (lxlO'^M) we would have expected the growth time course 
experiments of MCF-7 and ZR-75 cells to demonstrate cell proliferation greater than 
the control.
In the context of the study by Leake et al., (1992) these results demonstrate that 
Norethisterone (lxlO"^M) does not affect the ability of Tamoxifen to induce the 
synthesis of PR However, higher concentrations of Norethisterone significantly 
reduce this effect. Therefore, the dose of Norethisterone administered throughout the 
cyclical trial must be large enough to prevent vaginal bleeding in the post-menopausal 
patients but low enough so not to interfere with Tamoxifen’s induction of PR 
synthesis.
Tamoxifen is administered to patients as an anticancer treatment which acts 
primarily via the oestrogen receptor. This antiestrogen demonstrates an ability to 
induce PR synthesis almost equivalent to Oestradiol. Tamoxifen’s inability to interfere 
with the ER’s induction of PR synthesis suggests that Tamoxifen’s antiestrogenic 
properties he outwith this phenomenon.
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